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BIOLOGY & GENETICS 
Advancing Research on Stored Biological 
Materials: Reconciling Law, Ethics, and 
Practice 
Leslie E. Wolf 
I.  INTRODUCTION 
How would you feel if your biological materials (blood, skin 
cells, or the like) were used to develop sperm in a lab?1 What if 
                                                          
 2010 Leslie E. Wolf. 
 Leslie E. Wolf is an Associate Professor of Law at Georgia State University’s 
College of Law.  She conducts research in a variety of areas in health and 
public health law and ethics, with a particular focus on research ethics. She 
has conducted empirical research on conflicts of interest, research with stored 
biological materials, Certificates of Confidentiality, IRB web guidance, and 
HIV-related laws and policies.  Prior to joining the law school, Professor Wolf 
taught medical ethics and research ethics at the University of California, San 
Francisco, where she also served on the UCSF institutional review board and 
advisory committee regarding stem cell research. She also previously was 
selected as a Greenwall Fellow in Bioethics and Health Policy and as a 
Greenwall Faculty Scholar.  Professor Wolf teaches courses on human subjects 
research, public health law, HIV and the law, and health law liability.  She 
also is a member of the Centers for Disease Control and Prevention Ethics 
Subcommittee of the Advisory Committee to the Director.  
 1. Researchers already have developed mice sperm cells that have led to 
health offspring. Ker Than, Healthy Offspring Born from Lab-Grown Sperm, 
LIVESCIENCE, July 11, 2006, available at 
www.livescience.com/animals/060711_stemcell_sperm.html. A British team of 
researchers recently announced that they had developed human sperm from 
embryonic stem cells. Cell Medicine, Human Sperm Created from Embryonic 
Stem Cells, available at http://www.cellmedicine.com/ british-ivd-sperm.asp 
(last visited Oct. 23, 2009). The British research report has since been 
retracted. Retraction, 9 STEM CELLS & DEV. 1111 (2009). But we can anticipate 
that sperm ultimately will be derived from stem cells, which requires some 
human biological materials. Although many human embryonic stem cells are 
derived from excess human embryos from in vitro fertilization efforts, other 
human biological specimens may be used to create them, either by using the 
nucleus in somatic cell nuclear transfer (or cloning) or, more recently, by 
inducing somatic cells (e.g.,) into an embryonic state (induced pluripotent stem 
cells). Gina Kolata, Scientists Bypass Need for Embryo to Get Stem Cells, N.Y. 
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the research were conducted without your knowledge or 
consent? Most Americans are likely unaware that their 
biological materials have been stored and been made available 
for research.2 Stored biological materials come from a variety of 
sources, such as newborn blood spots taken for screening 
purposes; blood, tissues, and other materials taken for clinical 
diagnostic purposes; blood or DNA taken for forensic purposes; 
and materials collected specifically for research purposes.3 As 
described more fully below, federal regulations permit existing 
specimens to be used in research without the consent of the 
individuals who provided the materials. Such materials are an 
important resource for biomedical research and have been 
responsible for many scientific advances.4 
                                                          
TIMES, Nov. 21, 2007, at A1; see also, National Institutes of Health, Stem Cell 
Basics, http://stemcells.nih.gov/info/basics/ (last visited Feb. 15, 2010) 
(describing the basics of stem cells). 
 2. In 1998, an estimated 282 million biological specimens were stored in 
the United States, to which an estimated 20 million have been added each 
year. U.S. NAT’L BIOETHICS ADVISORY COMM’N, RESEARCH INVOLVING HUMAN 
BIOLOGICAL MATERIALS: ETHICAL ISSUES AND POLICY GUIDANCE 1 (1999), 
available at http://govinfo.library.unt.edu/nbac/hbm.pdf [hereinafter NBAC]. 
These specimen estimates refer to individual biological material; multiple 
specimens may come from a single source (e.g. from a single blood draw). Id. at 
13. The stored specimens came from more than 176.5 million individuals. Id. 
at 14. This number represents 65% of the U.S. population in 1999. U.S. 
Bureau of the Census, Historical National Population Estimates: July 1, 1900 
to July 1, 1999, 
http://www.census.gov/population/estimates/nation/popclockest.txt (last visited 
Aug. 20, 2009). Most of the stored specimens were obtained without consent 
for research. Eric M. Meslin & Kimberly A. Quaid, Ethical Issues in the 
Collection, Storage, and Research Use of Human Biological Materials, 144 J. 
LABORATORY & CLINICAL MED. 229, 230 (2004). 
 3. NBAC, supra note 2, at 1–2. 
 4. For example, stored human biological materials have been critical in 
identifying genes and gene changes associated with disease or disease 
susceptibility. See, e.g., Henry T. Greely, Iceland’s Plan for Genomics 
Research: Facts and Implications, 40 JURIMETRICS 153 (2000); Jeff M. Hall et 
al., Linkage of Early Onset Breast Cancer to Chromosome 17q21, 250 SCI. 1684 
(1990); Ragnheidur Haraldsdóttir, Letter to the Editor, Iceland’s Central 
Database of Health Records, 283 SCI. 487 (1999); Christoph Lengauer et al., 
Genetic Instability in Colorectal Cancers, 386 NATURE 623 (1997) (looking at 
colorectal cancer cell lines). For examples of using stored biological materials 
in determining causes of mortality and morbidity, see Arthur L. Herbst et al., 
Adenocarcinoma of the Vagina, 284 NEW ENG. J. MED. 878 (1971); Arthur L. 
Herbst & Robert E. Scully, Adenocarcinoma of the Vagina in Adolescence, 25 
CANCER 745 (1970); Arthur L. Herbst et al., Clear-Cell Adenocarcinoma of the 
Vagina and Cervix in Girls: Analysis of 170 Registry Cases, 119 AM. J. 
OBSTETRICS & GYNECOLOGY 713 (1974); Sylvia Wrobel, Serendipity, Science 
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However, some individuals may object to at least some uses 
of their biological materials.5 Most recently, the case of 
Washington University v. Catalona drew attention to legal and 
ethical issues that can arise in research involving stored 
biological materials.6 Catalona arose from a dispute, between 
Dr. Catalona, an internationally known prostate cancer 
researcher, and his former academic institution, regarding who 
should have control of biological materials collected over 
decades and stored for research use. Washington University 
sought a declaratory judgment establishing its ownership of the 
materials, and Dr. Catalona counterclaimed that the 
participants should have the right to direct the transfer of their 
materials to him.7 Eight research participants who donated 
their biological materials sought to intervene in the case to 
support Dr. Catalona’s claim to their materials. Ultimately, 
these men were joined as necessary parties to the case.8  As has 
been true in other cases, the Catalona court showed little 
                                                          
and a New Hantavirus, 9 FASEB J. 1247 (1995); CTRS. FOR DISEASE CONTROL 
& PREVENTION, NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY 
20072008: OVERVIEW (2007), available at  
http://www.cdc.gov/nchs/data/nhanes/nhanes_07_08/overviewbrochure_0708.p
df. For examples of deriving cell lines for further research, see U.S. NAT’L 
BIOETHICS ADVISORY COMM’N, ETHICAL ISSUES IN HUMAN STEM CELL 
RESEARCH  (1999); Rebecca Skloot, Henrietta’s Dance, JOHNS HOPKINS MAG., 
April 2000 [hereinafter Skloot, Henrietta’s Dance]; Rebecca Skloot, Cells that 
Save Lives are a Mother’s Legacy, N.Y. TIMES, Nov. 17, 2001, at A15 
[hereinafter Skloot, A Mother’s Legacy]. Stored biological materials have also 
been used to develop  new approaches to therapy such as pharmacogenetics, 
see Urs A. Meyer, Pharmacogenetics and Adverse Drug Reactions, 356 LANCET 
1667 (2000); C. Roland Wolf et al., Science, Medicine, and the Future: 
Pharmacogenetics, 320 BRIT. MED. J. 987 (2000). 
 5. There have been several instances in which people have brought 
lawsuits to assert their objections to use of their biological materials for 
research purposes. These include Moore v. Regents of the Univ. of Cal., 793 
P.2d 479 (Cal. 1990); Greenberg v. Miami Children’s Hosp. Research Inst., 
Inc., 264 F. Supp. 2d 1064 (S.D. Fla. 2003); Wash. Univ. v. Catalona (Catalona 
II), 490 F.3d 667 (8th Cir. 2007), cert denied, 128 S.Ct. 1122 (2008); and 
Havasupai Tribe v. Ariz. Bd. of Regents, 204 P.3d 1063 (Ariz. Ct. App. 2008), 
discussed infra Section III. Other instances people objecting to unauthorized 
use of their biological materials have been reported in the literature. For 
example, family members have objected to use of a well-known and widely 
used cell-line that was developed from materials originally taken from their 
mother without her knowledge or consent. Skloot, Henrietta’s Dance, supra 
note 4; Skloot, A Mother’s Legacy, supra note 4. 
 6. Wash. Univ. v. Catalona (Catalona I), 437 F. Supp. 2d 985 (E.D. Mo. 
2006). 
 7. Catalona II, 490 F.3d at 672. 
 8. Id. at 673. 
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sympathy for the research participants’ claims which could 
impede medical research that may benefit society.9 
Consistent with the federal regulations regarding such 
research, the Catalona courts saw little harm in using the 
research participants’ stored biological materials in research, 
even though, in this instance, the research participants were 
objecting to the continued use of their biological materials, at 
least at Washington University.10 The underlying assumptions 
of the federal regulations are that there are few risks involved 
in research on stored materials and that most people would 
agree to such participation. However, those assumptions, may 
no longer be valid in an era of whole-genome sequencing and 
large DNA databases, especially as genomic research is 
increasingly performed on sensitive issues such as IQ, ancestry, 
and personality traits.11 Moreover, those assumptions are not 
reasonable in the face of objections. 
In this article, I argue that it is time to reconsider our 
regulatory approach to research involving stored biological 
materials to better reflect the risks presented by such research 
and the concerns that some people have about use of their 
materials. In Section II, I analyze the court cases that address 
research with stored biological materials to identify how courts 
have characterized research participants’ interests in their 
materials. In Section III, I analyze how the federal regulations 
governing human-subject research protect those interests, and 
the limitations of those protections. In Section IV, I present and 
evaluate empirical data from a national survey of Institutional 
Review Board (“IRB”) Chairs that demonstrates that IRB 
Chairs often are reluctant to use the federal regulations to 
allow research on stored materials without consent when the 
proposed use is different from the purpose for which the 
materials were originally collected. I also present empirical 
data regarding investigator practices in research on stored 
materials, as well as empirical data from the literature 
                                                          
 9. Catalona I, 437 F. Supp. 2d at 1002  (stating that “[i]f left unregulated 
and to the whims of a [research participant], these highly-prized biological 
materials would become nothing more than chattel going to the highest 
bidder.”). 
 10. Id.; Catalona II, 490 F.3d at 676. 
 11. Deborah A Bolnick et al., The Science and Business of Genetic Ancestry 
Testing, 318 SCI. 399, 399 (2007); Kenneth Offitt, Genomic Profiles for Disease 
Risk: Predictive or Premature?, 299 JAMA 1353, 1353 (2008). 
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concerning participant preferences regarding consent and 
control over their donated biological materials. Taken together, 
these data recommend recognizing donor control over the 
research use of materials, even though this right of control is 
not fully recognized in the court opinions and in the federal 
regulations. Finally, in Section V, I make recommendations for 
changing the federal regulations and guidance to take into 
account the changing scientific landscape, risks to participants, 
and preferences evidenced by the empirical data. This can be 
done without unnecessarily impeding research involving stored 
biological materials. 
II.  HOW COURTS HAVE RESPONDED TO PEOPLE WHO 
HAVE OBJECTED TO THE USE OF THEIR BIOLOGICAL 
MATERIAL IN RESEARCH 
A.  MOORE V. REGENTS OF THE UNIVERSITY OF CALIFORNIA 
Our discussion begins with the case of Moore v. Regents of 
the University of California,12 the first, and for a long time, the 
only case on research use of biological materials. Moore is 
unique in that Mr. Moore was a patient and the biological 
materials at issue were collected in the clinical setting but 
applied to research and later commercial use. This clinical 
context may have colored the court’s view of Mr. Moore’s 
claims. 
1.  The Facts 
John Moore went to the University of California Los 
Angeles (UCLA) Medical Center in October 1976 for treatment 
for hairy-cell leukemia.13 His doctor, David Golde, drew blood, 
bone marrow, and other bodily substances from Mr. Moore to 
confirm his diagnosis, and ultimately recommended that Mr. 
Moore have his spleen removed to slow down the progression of 
                                                          
 12. Moore v. Regents of the Univ. of Cal.,793 P.2d 479 (Cal. 1990). 
 13. Id. at 481.  Hairy cell leukemia is a blood and bone marrow cancer in 
which the bone marrow makes abnormal lymphocytes (a white blood cell), 
which look hairy when viewed under a microscope. As these abnormal 
lymphocytes proliferate, they build up in the blood and bone marrow and 
crowd out other blood cells, such as healthy white blood cells, red blood cells, 
and platelets. If the cells collect in the spleen, it may swell. National Cancer 
Institute, General Information About Hairy Cell Leukemia, 
http://www.cancer.gov/cancerinfo/pdq/treatment/hairy-cell-leukemia/patient/ 
(last visited Nov. 4, 2009). 
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disease. Mr. Moore consented in writing. 14 
Over the next 7 years (from November 1976 to September 
1983), Mr. Moore returned to UCLA from his home in Seattle 
several times. He understood from Dr. Golde that such visits 
were required for his care.15 At each visit, Dr. Golde took 
samples of Mr. Moore’s blood, blood serum, skin, bone marrow, 
and sperm.16 Dr. Golde told Mr. Moore, when asked, that the 
specimen collections could only be performed at UCLA under 
Dr. Golde’s supervision.17 
In 1979, Dr. Golde established a cell line from Moore’s T-
lymphocytes. As explained by the court, 
A T-lymphocyte is a type of white blood cell. T-lymphocytes produce 
lymphokines, or proteins that regulate the immune system. Some 
lymphokines have potential therapeutic value. If the genetic material 
responsible for producing a particular lymphokine can be identified, it 
can sometimes be used to manufacture large quantities of the 
lymphokine through the techniques of recombinant DNA.18 
Mr. Moore’s T-lymphocytes were valuable because they 
overproduced certain lymphokines, making it easier to identify 
the gene responsible for the lymphokine.19 The University 
Regents filed for a patent on the cell line, called “Mo,” and the 
method for producing lymphokines from the cell line in 
January 1981; the patent was issued in March 1984.20 Dr. 
Golde was listed as an inventor on the patent and, pursuant to 
UCLA policy, was eligible to share in any royalties or profits 
from the patent.21 UCLA and Dr. Golde negotiated development 
agreements with respect to the cell line that provided Dr. Golde 
with salary support and stock.22 Reportedly, Dr. Golde received 
75,000 shares of stock in Genetics Institute Inc., and both Dr. 
Golde and UCLA received $440,000 in research grants from 
Genetics Institute Inc. and Sandoz Pharmaceutical Corp. to 
develop products using the patent.23 
                                                          
 14. Moore, 793 P.2d at 481. 
 15. Id. 
 16. Id. 
 17. Id.; see also Dennis McLellan, John Moore, 56; Sued to Share Profits 
from His Cells, L.A. TIMES, Oct. 13, 2001, at B16. 
 18. Moore, 793 P.2d at 481 n.2.  
 19. Id. at 48182. 
 20. Id.; see also McLellan, supra note 17. 
 21. Moore, 793 P.2d at 482. 
 22. Id. 
 23.  Philip Hager, Justices Deny Patients’ Rights to Tissue Profits, L.A. 
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At some point during the seven years, Moore became 
suspicious about Dr. Golde’s actions. When he asked 
specifically about the potential financial value of his cells, Dr. 
Golde denied such value.24 In 1983, Mr. Moore signed a consent 
form to participate in a research study, but refused to sign over 
any rights he had in any cell line or any potential product that 
might be developed from any tissue samples obtained from 
him.25 In his lawsuit, Moore alleged that the reason Golde 
required him to come to UCLA was because Golde wanted to 
obtain more of Moore’s cells to use in research from which 
Golde might benefit financially.26 
2.  The Legal Proceedings 
John Moore sued Dr. Golde, among others, upon learning 
of the use of his bodily materials to create a cell line.27 In 
support of his claims, Mr. Moore alleged that Dr. Golde knew 
that some of his blood products and components had both 
commercial and scientific value before his surgery and that Dr. 
Golde decided to use his spleen for research before the surgery, 
but did not inform him of this intention.28 The defendants 
successfully demurred to all of Mr. Moore’s causes of action at 
the trial court.29 The Court of Appeal reversed the trial court’s 
decision.30 The California Supreme Court granted review of the 
Court of Appeal decision.31 Following its decision, only the 
cause of action for breach of the physician’s disclosure 
obligations survived.32 
The California Supreme Court described the surviving 
                                                          
TIMES, July 10, 1990, at A1. 
 24. Moore, 793 P.2d at 485–86. 
 25. ROBERT F. WEIR & ROBERT S. OLICK, THE STORED TISSUE ISSUE: 
BIOMEDICAL RESEARCH, ETHICS, AND LAW IN THE ERA OF GENOMIC MEDICINE 
5–6 (2004). 
 26. Moore, 793 P.2d at 481. 
 27. His claims included causes of action for: (1) “Conversion,” (2) “lack of 
informed consent,” (3) “breach of fiduciary duty,” (4) “fraud and deceit,” (5) 
“unjust enrichment,” (6) “quasi-contract,” (7) “bad faith breach of the implied 
covenant of good faith and fair dealing,” (8) “intentional infliction of emotional 
distress,” (9) “negligent misrepresentation,” (10) “intentional interference with 
prospective advantageous economic relationships,” (11) “slander of title,” (12) 
“accounting,” and (13) “declaratory relief.” Id. at 482 n.4. 
 28. Id. at 481. 
 29. Id. at 482. 
 30. Id. at 483. 
 31. Moore, 793 P.2d at passim. 
 32. Id. at 480. 
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cause of action as being “properly . . . characterized either as 
the breach of a fiduciary duty to disclose facts material to the 
patient’s consent or, alternatively, as the performance of 
medical procedures without first having obtained the patient’s 
informed consent”.33 Basic principles of informed consent led 
the court to conclude that: 
(1) a physician must disclose personal interests unrelated to the 
patient’s health, whether research or economic, that may affect the 
physician’s professional judgment; and (2) a physician’s failure to 
disclose such interests may give rise to a cause of action for 
performing medical procedures without informed consent or breach of 
fiduciary duty.34 
The court took pains to mention that it is not unlawful for 
a physician to conduct research in his practice area; indeed, 
such research may benefit patients like Mr. Moore. 
Nevertheless, a patient is entitled to know about the conflicting 
loyalties that may exist when a physician is also a researcher.35 
It is important to note where the court’s concern lies. It is 
not in the use of Mr. Moore’s biological materials without his 
consent. Rather, it is the failure of Dr. Golde to inform Mr. 
Moore of Golde’s research interest in these materials that was 
different from, and could affect, Moore’s medical interests. 
Indeed, the court notes: 
If a physician has no plans to conduct research on a patient’s cells at 
the time he recommends the medical procedure by which they are 
taken, then the patient’s medical interests have not been impaired… . 
On the other hand, a physician who does have a preexisting research 
interest might, consciously or unconsciously, take that into 
consideration in recommending the procedure. In that instance . . . 
the physician’s extraneous motivation may affect his judgment and is, 
thus, material to the patient’s consent.36 
The court specifically rejected Mr. Moore’s claim of 
conversion of his biological materials, “a tort that protects 
against interference with possessory and ownership interests in 
personal property.”37 According to the court, Mr. Moore was 
arguing that “he continued to own his cells following their 
removal from his body, at least for the purpose of directing 
their use, and that he never consented to their use in 
                                                          
 33. Id. at 483. 
 34. Id.  
 35. Id. at 483–84. 
 36. Id. at 484. 
 37. Id. at 487. 
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potentially lucrative medical research.”38 The court declined to 
accept this argument, concluding that it would place too much 
of a burden on science. 
In effect, what Moore is asking us to do is to impose a tort duty on 
scientists to investigate the consensual pedigree of each human cell 
sample used in research. To impose such a duty, which would affect 
medical research of importance to all of society, implicates policy 
concerns far removed from the traditional, two-party ownership 
disputes in which the law of conversion arose. Invoking a tort theory 
originally used to determine whether the loser or the finder of a horse 
had the better title, Moore claims ownership of the results of socially 
important medical research, including the genetic code for chemicals 
that regulate the functions of every human being’s immune system.39 
The court reasoned that: 
[T]here are several reasons to doubt that he did retain any such 
[ownership] interest. First, no reported judicial decision supports 
Moore’s claim, either directly or by close analogy. Second, California 
statutory law drastically limits any continuing interest of a patient in 
excised cells. Third, the subject matters of the Regents’ patentthe 
patented cell line and the products derived from itcannot be Moore’s 
property.40 
Moore turned to cases regarding unauthorized use of 
likeliness to try to support his conversion claim. The court 
rejected this analogy to privacy laws by pointing, not to the 
uniqueness of Mr. Moore’s cells (or their uniqueness to him), 
but rather to the purpose for which they were used. The goal 
was to create lymphokines, which are not unique to 
individuals.41 Following the California Supreme Court’s 
decision, Mr. Moore and UCLA reached what Mr. Moore 
referred to as a “token” settlement.42 He was quoted as saying: 
“Without my knowledge or consent, the doctors and the 
research institutions used a part of me for their own gain. They 
stole something from me.”43 He also reportedly stated: 
To learn that their position was that they owned a part of me. . . . I 
think demeaned is a good word. . . . There was a sense of betrayal. . . . 
I means why didn’t he just tell me?. . . To me, it was a total invasion 
of a person’s right to control the use of their own genetic code, their 
own flesh and blood. . . . I certainly have no objection to scientific 
research . . . but it was like rape. In a sense you have been violated… 
                                                          
 38. Id. 
 39. Id. at 487–88 (footnotes omitted). 
 40. Id. at 489 (although the court does recognize in n.20 that Moore does 
not seek actual possession of his cells). 
 41. Id. at 490. 
 42. McLennan, supra note 17. 
 43. Id.  
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3.  Implications 
Although only binding in California, Moore’s influence has 
been felt well beyond California’s borders and, for a decade, 
was the sole case addressing an individual’s interests in the use 
of the biological materials derived from his body for research. 
The case is useful to those engaging in biobanking, because it 
indicates that individuals do not retain interests in their 
biological materials when they are outside the body.45 But it is 
important to remember the context in which the case  arose. 
Mr. Moore was a patient first and his biological materials were 
collected during his medical treatment and used in research. 
That clinical context may help to explain the court’s decision. 
First, the biological materials that Dr. Golde used and 
later patented were generally thought to be clinical waste.46 
Had Dr. Golde discarded the spleen, Mr. Moore would have had 
no complaint; few people want or expect to receive the 
materials that are removed during surgery. Indeed, hospitals 
are expected to get rid of medical waste properly. Second, no 
one questioned the quality or appropriateness of the surgical 
care that Dr. Golde provided Mr. Moore. On the other hand, the 
doctors’ concealment of their financial interests in Mr. Moore’s 
cells, while asking Mr. Moore to make multiple trips from his 
Seattle home to Los Angeles, seemed to be a violation of the 
doctor’s duty to act in the best interests of his patient. Thus, 
the court talked about physicians’ obligations to disclose 
financial interests to patients; the court did not explicitly 
discuss researchers’ obligations to disclose financial interests 
when collecting biological materials from research participants 
(although California research institutions have interpreted it 
as doing so). 47 Nor does the court consider what rights research 
                                                          
 44. WEIR & OLICK, supra note 25, at 9. 
 45. “Biobanks,” also referred to as “biorepositories,” are places that collect 
and store samples of biological material, such as urine, blood, tissue, cells, 
DNA, and RNA for research. They may also include medical information about 
individuals whose biological material are stored. See National Cancer 
Institute, U.S. National Institutes of Health: Dictionary of Cancer Terms, 
www.cancer.gov/dictionary/?CdrID=561323 (last visited Feb. 11, 2010); see 
also Eve-Marie Engels, Biobanks as Basis for Personalised Nutrition? 
Mapping the Ethical Issues, 2 GENES & NUTRITION 59, 59 (2007). 
 46. See Moore, 793 P.2d at 491–92. 
 47. See, e.g., sample consent form language from the University of 
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participants might have under the federal regulations.48 
B.  GREENBERG V. MIAMI CHILDREN’S HOSPITAL RESEARCH 
INSTITUTE, INC.49 
1.  The Facts 
The Greenberg case arose out of parents’ efforts to find a 
genetic test for Canavan disease, a fatal, inherited, 
degenerative brain disease that was affecting their children.50 
Children born with Canavan disease suffer from imperfect 
development of the myelin sheath, the fatty covering around 
nerve fibers in the brain.51 Over time, build up of chemicals 
causes the brain to become spongy. Symptoms appear early in 
infancy (3–6 months) and progress rapidly. They include 
mental retardation, loss of previously acquired motor skills, 
feeding difficulties, floppiness or stiffness in muscles, and an 
increasing head circumference.52 Children with Canavan 
disease do not crawl, walk, sit, or talk. Over time, they may 
have seizures, paralysis, blindness, or hearing loss.53 Children 
with this disease typically die before they are 4 years old.54 
Canavan disease is a recessive genetic condition. That is, a 
person who carries one copy of the gene is not affected. 
However, if both parents carry a copy of the gene, there is a 1 
in 4 chance (25%) with each pregnancy that the disease will 
affect their child.55 Although it can occur in any ethnic group, 
Canavan disease is more frequent among people of Ashkenazi 
                                                          
California, San Francisco, UCSF Guidance on Research Topics and Issues,  
http://www.research.ucsf.edu/chr/Guide/chrHumanBioSpec.asp (last visited 
Nov. 4, 2009). University of California guidance incorporates this language in 
response to the lawsuit. OFFICE OF THE PRESIDENT, UNIV. OF CAL., 
SYSTEMWIDE IRB DIRECTORS MEETING SUMMARY 1 (2008). 
 48. 45 C.F.R. § 46.101.124 (2009). 
 49. Greenberg v. Miami Children’s Hosp. Research Inst., Inc., 264 F. 
Supp. 2d 1064 (S.D. Fla. 2003). 
 50. See  Canavan Foundation, What Is Canavan Disease?, 
http://www.canavanfoundation.org/canavan.php (last visited Nov. 4, 2009); 
National Institute of Neurological Disorders and Stroke, National Institute of 
Health, NINDS Canavan Disease Information Page, 
http://www.ninds.nih.gov/disorders/canavan/canavan.htm (last visited Nov. 4, 
2009) [hereinafter NINDS Canavan]. 
 51. Canavan Foundation, supra note 50. 
 52. Id. 
 53. Id. 
 54. NINDS Canavan, supra note 50. 
 55. Id. 
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Jewish descent from eastern Poland, Lithuania, and western 
Russia, as well as among people of Saudi Arabian descent.56 
In 1987, there was no test for Canavan disease. Thus, 
potential parents could not ascertain whether they were at risk 
for having a baby with Canavan disease. Parents of children  
with Canavan disease could not test their fetus to know if it 
was affected.57 At that point, Daniel and Debbie Greenberg, 
who had lost two children to Canavan disease, approached Dr. 
Matalon, a research physician then at the University of Illinois 
at Chicago, and proposed a research collaboration with the goal 
of developing a genetic test for Canavan disease.58 The 
Greenbergs and the Chicago Chapter of the National Tay-
Sachs59 and Allied Disease Association, Inc. (NTSAD) located 
other Canavan families to participate in the research by 
providing tissue (blood, urine, and autopsy samples), financial 
support, and help in finding other Canavan families.60 Dr. 
Matalon continued his relationship with the Greenbergs and 
the organization, including receipt of tissue and blood samples, 
medical information, and financial support, when he moved to 
Miami Children’s Hospital Research Institute, Inc. in 1990.61 
                                                          
 56. Id. 
 57. Greenberg v. Miami Children’s Hosp. Research Inst., Inc., 264 F. 
Supp. 2d 1064, 1066 (S.D. Fla. 2003). 
 58. Id. at 1067; see also, Chicago-Kent College of Law, Honors Scholar 
Class Project: Greenberg v. Miami Children’s Hospital et al., 
http://www.kentlaw.edu/honorsscholars/projects/greenberg.html (last visited 
Nov. 4, 2009) (discussing the facts of the case and the legal assistance 
provided by the Law School in regards to the lawsuit). 
 59. Tay-Sachs is a fatal genetic disorder affecting lipid (fat) storage. 
Children affected by Tay-Sachs develop build-up of a fatty substance 
(ganglioside GM2) in their tissues and nerve cells in their brain. Infants with 
Tay-Sachs appear to develop normally for their first few months, but as the 
fatty material builds up, their mental and physical abilities begin to 
deteriorate. Eventually, the child becomes blind, deaf, unable to swallow, and 
paralyzed. The child may also experience dementia, seizures, and an increased 
startle reflex. Most children die before age 4. As with Canavan, Tay-Sachs is a 
recessive genetic disorder that has particularly high incidence among people of 
Eastern European and Ashkenai Jewish descent. There is a 1 in 4 chance of 
having an affected child if both parents are carriers. A genetic test has been 
available for several decades.  National Institute of Neurological Disorders 
and Stroke, National Institute of Health, NINDS Tay-Sachs Disease 
Information Page,  http://www.ninds.nih.gov/disorders/taysachs/taysachs.htm 
(last visited Nov. 4, 2009) 
 60. Greenberg, 264 F. Supp. 2d at 1067. 
 61. Id.  
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In 1993, using the biological samples, family pedigree 
information, contacts, and financial support provided by the 
Greenbergs and other families affected by Canavan disease, Dr. 
Matalon successfully isolated the gene responsible for the 
disease.62 The families continued to provide materials to learn 
more about the disease. In 1994, Matalon applied to patent the 
genetic sequence that he had identified.63 The patent was 
granted in 1997.64 As a result of the patent, Matalon and 
Miami Children’s Hospital could “restrict any activity related to 
the Canavan disease gene, including: carrier and prenatal 
testing, gene therapy and other treatments for Canavan 
disease, and research involving the gene and its mutations.”65 
In 1998, the Greenbergs and other families who had 
participated in the collaboration learned of the patent and 
Miami Children’s Hospital’s plan to enforce the patent and seek 
exclusive licensing agreements and royalty fees from centers 
offering Canavan disease testing, an action that could limit 
access to testing.66 
2.  The Legal Proceedings 
In 2000, the Greenbergs, other parents of affected children, 
and the non-profit organizations involved in the research 
collaboration filed a complaint against Matalon and Miami 
Children’s Hospital, among others. Their causes of action 
included (1) lack of informed consent, (2) breach of fiduciary 
duty, (3) unjust enrichment, (4) fraudulent concealment, (5) 
conversion, and (6) misappropriation of trade secrets.67 The 
plaintiffs asserted that they had understood that: 
[A]ny carrier and prenatal testing developed in connection with the 
research for which they were providing essential support would be 
provided on an affordable and accessible basis, and that Matalon’s 
research would remain in the public domain to provide the discovery 
of more effective prevention techniques and treatments and, 
eventually, to effectuate a cure for Canavan disease.68 
The plaintiffs sought a permanent injunction against the 
                                                          
 62. Id.  
 63. Id. 
 64. Id.  
 65. Id. As is typical, Dr. Matalon was listed as inventor on the patent, but, 
because it was developed while he was employed by the Miami Children’s 
Hospital, the hospital held the license. 
 66. Id.  
 67. Id. at 1068. 
 68. Id. at 1067. 
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defendants from enforcing the patent rights, as well as 
damages in the form of reimbursement of royalties from the 
patent, estimated at over $75,000, as well as reimbursement of 
the financial contributions the plaintiffs had made to support 
the research.69 
3.  Implications 
The plaintiffs faced a motion to dismiss their complaint for 
failing to state a claim upon which relief could be granted.70 
The court granted this motion, except for the claim of unjust 
enrichment.71 But it is important to look at how the court 
approached some of these claims. The plaintiffs alleged in their 
complaint that defendants had breached their duty to obtain 
informed consent by failing to disclose information that might 
influence the families’ decision to participate or decline to 
participate in research. Specifically, plaintiffs claimed that the 
intent to file a patent application and enforce that patent was 
material and ought to have been disclosed. That is, had they 
been informed of the intent to “‘commercialize’ the results of 
their contributions,” they would not have contributed.72 On the 
other hand, the defendants contended that “there was no actual 
human experimentation as part of an ongoing relationship 
alleged in the complaint”; thus, there was no obligation to 
obtain informed consent.73 The court held that, although a duty 
of informed consent in medical research did attach at some 
point, the duty did not extend to disclosures of economic 
interests of researchers who are not also in a therapeutic 
relationship with the donor.74 As in Moore, the court expressed 
concern about the chilling effect on medical research that might 
result if it imposed such a duty of economic disclosure.75  With 
                                                          
 69. Id. at 1068. 
 70. Id. at 1066. 
 71. This claim likely survived because, in addition to providing biological 
materials and medical histories, the plaintiffs provided substantial financial 
support to the defendants for the research. Id. at 1072. This is a substantially 
different circumstance than, for example, in the Moore case, where John 
Moore supplied his cells but provided neither financial nor intellectual support 
for derivation of the resulting cell line. 
 72. Id. at 1068. 
 73. Id. at 1069. 
 74. Id. at 1070 (distinguishing Moore v. Regents of the Univ. of Cal., 793 
P.2d 479 (Cal. 1990)). 
 75. Id. at 1070. 
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respect to the claim of conversion, the court, as the Moore court 
did, refused to find any “contemporaneous expectations of 
return of the body tissue and genetic samples” when they were 
donated, and thus, found no cause of action.76 This theory 
depended on a property interest, which the court did not find. 
However, the decision failed to recognize other interests 
plaintiffs might have in controlling the uses to which their 
bodily materials were put. 
C.  WASHINGTON UNIVERSITY V. CATALONA77 
1.  The Facts 
Dr. Catalona was an internationally renowned urologist, 
urologic surgeon, and medical researcher, who also developed 
the prostate-specific antigen (PSA) test used for prostate cancer 
screening. From 1976-2003, Dr. Catalona was employed at 
Washington University (WU).78 Dr. Catalona conducted 
research concerning the genetic basis of prostate cancer.79 To 
further this goal, Dr. Catalona played a substantial role in 
establishing the Genitourinary (GU) Biorepository at 
Washington University, which stored, maintained, and 
distributed the biological specimens collected by Dr. Catalona 
and other WU physicians.80 
                                                          
 76. Id. at 1074. 
 77. Wash. Univ. v. Catalona (Catalona II), 490 F. 3d. 667 (8th Cir. 2007) 
cert. denied, 128 S.Ct. 1122 (2008). 
 78. Id. at 670; Urological Research Foundation, The Site for Prostate 
Cancer Information from Dr. William Catalona, 
http://www.drcatalona.com/default.asp (last visited Nov. 4, 2009). Washington 
University is renowned in its own right. It is a private research university in 
St. Louis, Missouri, that includes a prestigious medical school. Catalona II, 
490 F.3d at 670. The medical school was ranked 4th among medical schools in 
National Institutes of Health research awards in fiscal year 2005. National 
Institutes of Health, NIH Awards to Medical Schools by Rank Fiscal Year 
2005, http://report.nih.gov/award/rank/medttl05.htm (last visited Nov. 19, 
2009) (2005 is the last year for which NIH provided ranked data). The medical 
school was ranked 3rd for research by the U.S. News and World Report in 
2009. U.S. News & World Report, Research Rankings: Best Medical Schools, 
http://grad-schools.usnews.rankingsandreviews.com/best-graduate-schools/top-
medical-schools/research-rankings (last visited Nov. 4, 2009). 
 79.  Catalona II, 490 F.3d at 670. 
 80. Id. at 671–72. To give a sense of the size of the GU Repository, when 
the permanent injunction hearing was held, there were 3,500 prostate tissue 
samples from WU patients, 100,000 blood or serum samples from over 28,000 
men (75% of whom were not WU patients), and DNA samples from 4,400 men 
(including WU patients and patients’ family members). Id. 
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In 2003, Dr. Catalona accepted a faculty position at 
Northwestern University.81 To facilitate his continued research 
on the genetics of prostate cancer, he sent a letter to his 
patients and research participants asking that they agree to 
transfer their stored biological materials to Northwestern.82 In 
all, between 50,000 and 60,000 research participants received 
his letter, and about 6,000 returned the transfer agreement 
which stated: 
I have donated a tissue and/or blood sample for Dr. William J. 
Catalona’s research studies. Please release all of my samples to Dr. 
Catalona at Northwestern University upon his request. I have 
entrusted these samples to Dr. Catalona to be used only at his 
direction and with his express consent for research projects.83 
The materials collected in the GU Biorepository had been 
obtained from individuals who consented to participate in 
genetic research. Their consent was documented in written 
consent forms.84 The court of appeals noted several relevant 
clauses from the consent forms. First, they “often used the term 
‘donation’ to describe the biological sample’s transfer from the 
[research participant] to a WU physician or medical 
technician.”85 They also typically included a provision in which 
the research participant “agree[s] to waive any claim [he] might 
have to the body tissues that [he] donate[s]” and “waive[s] the 
right to any new material or process developed through 
research involving [his] tissues.”86 Finally, participants had 
been informed that “[y]our participation is voluntary and you 
may choose not to participate in this research study or 
withdraw your consent at any time,” with some of the forms 
(but not all) noting that research participants could ask that 
their materials be destroyed if they decided to withdraw, but 
they could not ask that results already obtained be destroyed.87 
The right to request destruction of materials was also 
contained in a genetic research information brochure given to 
research participants to review and sign.88 
                                                          
 81. Id. at 672. 
 82. Id.  
 83. Id.  
 84. Id. at 671. 
 85. Id.  
 86. Id. Because Dr. Catalona conducted prostate cancer research, all 
research participants were male. 
 87. Id. 
 88. Id.  
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2.  The Legal Proceedings 
Washington University filed a declaratory judgment action 
against Dr. Catalona to establish its ownership of the samples 
in the GU biorepository. Dr. Catalona counterclaimed, seeking 
a declaration of the research participants’ rights to transfer the 
materials to him.89 After Washington University moved for 
summary judgment, Dr. Catalona moved for a preliminary 
injunction, and after numerous delays, the trial court held a 
hearing on whether to grant a permanent injunction.90 Before 
the hearing, eight of Dr. Catalona’s patients who were also 
research participants sought to intervene in the litigation.91 
The court found the research participants were necessary 
parties to the litigation and they were joined as defendants.92 
The district court found in favor of WU, concluding that 1) WU 
was the owner of the biological materials, 2) neither Dr. 
Catalona nor the research participants had any ownership 
interest in the specimens, and 3) the transfer agreements 
signed by the research participants had no legal effect.93 Dr. 
Catalona appealed the ruling.94 The court of appeals stated the 
question on appeal: “We are asked to determine the ownership 
of biological materials contributed by individuals for the 
purpose of genetic cancer research and currently housed on the 
campus of Washington University.”95 
The court of appeals ultimately affirmed “the well-reasoned 
opinion and judgment of the district court.”96 The court of 
appeals agreed with the district court that the research 
participants had made an inter vivos gift of their materials.97 In 
support of its conclusion, the court pointed out that the 
research participants were informed that they would not have 
control over the materials; for example, the brochure made 
clear that materials could be shared with non-WU researchers 
                                                          
 89. Id. at 672. 
 90. Id. at 673. 
 91. Id. 
 92. Id.  
 93. Id.; Wash. Univ. v. Catalona (Catalona I), 437 F. Supp. 2d. 985, 1002 
(E.D. Mo. 2006).  
 94. Wash. Univ. v. Catalona (Catalona II), 490 F. 3d. 667, 673 (8th Cir. 
2007) cert. denied, 128 S.Ct. 1122 (2008). 
 95. Id. at 670. 
 96. Id. at 677. 
 97. Id. at 674. 
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without further permission.98 That the research participants 
retained some rights, specifically the right to request 
destruction of the materials, did not alter the court of appeals’ 
view that WU had control over the materials.99 
3.  Implications 
Neither the district court nor the court of appeals was 
particularly sympathetic to the participants’ interests. Unlike 
the court of appeals, which noted that the donation was 
conditioned on the right to withdraw, the district court rejected 
the claim that research participants who agreed to give 
researchers their biological materials for research had a right 
to withdraw their specimens.100 The court stated that: “There is 
nothing stated in the governing federal regulations which 
equates a right to discontinue participation with a right to 
control the disposition and use of the excised biological 
materials.”101 Supporting this position, the court pointed to 
testimony that, when a participant discontinued participation, 
three things could happen: “1) WU may destroy the sample; 2) 
WU may store the sample indefinitely without any further use; 
or 3) WU may remove all identifying markers and use the 
sample in exempt “anonymized” research.”102 Indeed, the court 
went on to note that “[n]o one questioned WU’s ability to simply 
store the samples indefinitely after a [research participant] 
discontinue[d] participation in a research project.103 Finally, 
Dr. Ludbrook and Prentice both testified that anonymization 
[was] a response available to WU when a [research participant] 
[chose] to discontinue participation in research.”104 As a result, 
The Court [found] that the right to discontinue participation in a 
                                                          
 98. Id.  
 99. Id.  
 100. Wash. Univ. v. Catalona (Catalona I), 437 F. Supp. 2d 985, 9991000 
(E.D. Mo. 2006). 
 101. Id. at 999. 
 102. Id.  
 103. Id. 
 104. Id. Dr. Ludbrook was the WU IRB Chair, see, Washington University 
in St. Louis School of Medicine, Cardiovascular Division, Philip A. Ludbrook, 
http://cardiology.wustl.edu/details.aspx?NavID=571 (last visited Feb. 11, 
2010); Dr. Prentice is an expert in human subjects research, see Public 
Responsibility in Medicine and Research, 
www.primr.org/Aboutus.aspx?id=1250 (regarding Dr. Prentice’s receipt of the 
PRIM&R Distinguished Service Award) (last visited Feb. 11, 2010). 
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research project [meant] nothing more that the [research participant 
had] chosen not to provide any more biological materials pursuant to 
one or more research protocols; i.e., not to make any more inter vivos 
gifts of donated biological materials to WU. Nothing more can or 
should be read into this right possessed by the [research participant] 
at all times.105 
As discussed in section V below, the court’s conclusion (and 
the expert testimony on which it was based) fundamentally 
misread what the right to withdraw from participation in 
research, mandated by the federal regulations governing 
human subjects research, means when biological materials are 
collected and stored for research purposes. Underlying the 
court’s conclusion was the assumption that the only risks such 
research presents to donors are threats to confidentiality.106 
The cases discussed in this section, and the empirical data 
discussed in section III below, however, suggest otherwise. The 
court of appeals did not reject this conclusion (indeed, its 
endorsement of the lower court’s decision suggests it accepted 
it). Thus, the Catalona courts appeared to eliminate one of the 
few protections available to those who donate their biological 
materials to research who subsequently change their minds 
about the materials’ continued use. 
As in the Moore decision, the district court expressed 
concern about the public policy implications of allowing Dr. 
Catalona and the research participants to prevail in their 
claim. The court noted the value of biological materials to 
medical research: “Medical research can only advance if access 
to these materials to the scientific community is not thwarted 
by private agendas.” It went on to consider the consequences of 
honoring research participants’ wishes: “If left unregulated and 
to the whims of a [research participant (RP)], these highly-
prized biological materials would become nothing more than 
chattel going to the highest bidder.”107 The court went on to 
state: 
Allowing an RP to choose who can have the sample, where the sample 
will be stored, and/or how the sample can be used is tantamount to a 
blood donor being able to dictate that his/her blood can only be 
transfused into a person of a certain ethnic background, or a donated 
                                                          
 105. Id. at 1000. 
 106. It is also not clear whether the court would acknowledge such rights, 
given that it finds that Washington University’s agreement to apply the 
Belmont Principles does not form a basis for asserting research participants’ 
rights, because research participants are not parties or third-party 
beneficiaries to the agreement. Id. at 1000. 
 107. Id. at 1002. 
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kidney being transplanted only into a woman or man.108 
Even if the research participants did not have the right to 
transfer their materials to Dr. Catalona (at least under the 
terms of the consent forms that they signed), research 
participants could still have legitimate reasons for wishing to 
remove their biological materials and DNA from medical 
research. Indeed, the court of appeals noted that: “Noticeably 
absent from the record is any mention the [research 
participants] ever were informed they could physically 
withdraw or request the return of their biological samples.”109 
It is ironic that among those who have sought to remove 
their materials from research have done so not to prevent 
others from sharing the benefits of research, but rather to 
broaden access or to avoid exploitation and research viewed to 
denigrate a person’s racial or ethnic background. 110 
D.  HAVASUPAI V. ARIZONA STATE UNIVERSITY111 
1.  The Facts 
In 2004, the Havasupai tribe brought suit against Arizona 
State University (ASU) and some of its researchers for using 
their biological materials in research without their consent.112 
The name of the tribe, Havasuw ‘Baaja (Havasupai), translates 
to “the people of the blue green waters,” a reference to the 
                                                          
 108. Id.  
 109. Wash. Univ. v. Catalona (Catalona II), 490 F.3d 667, 676 (8th Cir. 
2007) cert. denied, 128 S.Ct. 1122 (2008). 
 110. See, e.g., Greenberg v. Miami Children’s Hosp. Research Inst., Inc., 
264 F. Supp. 2d 1064 (2003) (seeking to ensure broader access to genetic 
testing for Canavan disease); Havasupai Tribe v. Ariz. Bd. of Regents, 204 
P.3d 1063 (Ariz. Ct. App. 2008) (seeking return of materials to prevent use of 
tribal biological materials in research that is contrary to tribal beliefs or 
interests). 
 111. Havasupai Tribe, 204 P.3d at 1063. Although the appellate court notes 
that it takes the facts primarily from the Hart Reportthe independent 
investigation that ASU arrangedbecause of the procedural posture of the 
case, the appellate court viewed “the facts and the inferences . . . in the light 
most favorable to the [Havasupai] as the parties against whom summary 
judgments were entered.” Id. at 1067 n.2 (citing Prince v. City of Apache 
Junction, 912 P.2d 47, 49 (Ariz Ct. App. 1996)). 
 112. Id. at 1070. The Havasupai are not alone in their complaints. Other 
Natives Peoples have objected to research uses of their biological materials. 
See Rex Dalton, Tribe Blasts ‘Exploitation’ of Blood Samples, 420 NATURE 111, 
111 (2002). ETC Group, About ETC Group, http://etcgroup.org/en/about (last 
visited Nov. 4, 2009). 
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spectacular waterfalls that are located on their lands.113 The 
Havasupai are the “traditional guardians of the Grand 
Canyon.” According to Havasupai history, they have inhabited 
the canyon from the beginning.114 They believe that the retreat 
of waters from a global flood carved the Grand Canyon, which 
they consider the birthplace of the human race.115 The 
Havasupai are a federally recognized Native American tribe, 
with about 650 enrolled members.116  Approximately 450 
members live on the tribe’s reservation located near the Grand 
Canyon.117 
Because many in the tribe suffered from diabetes, in 1990 
the Havasupai requested assistance in understanding the 
cause of diabetes within the tribe.118 With the approval of the 
Tribal Council, who encouraged tribe members to participate, 
the ASU researchers ultimately collected over 200 blood 
samples from tribal members for diabetes research.119 
John Martin, an anthropology professor at ASU, had a 
long-standing relationship with the Havasupai. He had spent a 
year with the tribe in 1963 for his doctoral dissertation.120 Over 
decades, Dr. Martin had worked on a number of issues, 
including education, community action and development 
studies, and social and environmental studies.121 Based on 
their relationship with— and trust in— him, in 1989 the 
Havasupai asked Dr. Martin for assistance concerning the 
perceived epidemic of diabetes within the tribe.122 He brought 
in two other ASU researchers, Linda Vaughan, a professor in 
                                                          
 113. Betsey Bruner, People of the Blue-Green Water, ARIZ. DAILY SUN, 
Feb. 8, 2009, available at 
http://azdailysun.com/articles/2009/02/08/news/arts_and_entertainment/sunda
y_arts/20090208_sunda_190449.txt. 
 114. Grand Canyon Hotels & Tours, The Havasupai Tribe and Havasupai 
Waterfalls, http://www.grandcanyon.com/havasupai.html (last visited Nov. 18, 
2009). 
 115. Id. 
 116. Havasupai, About Havasupai, 
http://www.havasupaitribe.com/about.html (last visited Nov. 4, 2009). 
 117. Id. 
 118. Havasupai Tribe v. Ariz. Bd. of Regents, 204 P.3d 1063, 1067 (Ariz. 
Ct. App. 2008). 
 119. Id. 
 120. Id. at 1066; Paul Rubin, Indian Givers, PHOENIX NEW TIMES, May 27, 
2004, available at http://www.phoenixnewtimes.com/2004-05-27/news/indian-
givers. 
 121. Havasupai Tribe, 204 P.3d at 1066. 
 122. Rubin, supra note 120. 
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nutrition, and Therese Markow, a zoology professor with 
expertise in genetics.123 Dr. Markow expressed interest in 
expanding the diabetes study to other topics, including 
schizophrenia, although Martin told her that the tribe likely 
would not agree to such a study.124 The original diabetes study, 
including collection of blood, genetic research, and disease 
education, was funded by ASU.125 However, before blood was 
collected, Dr. Markow began seeking funding for schizophrenia 
research on the tribe.126 
In 2003, Dr. Martin reportedly made a phone call to a 
Havasupai tribal member, Carletta Tilousi, that ultimately led 
to the lawsuit against Dr. Martin and other ASU 
researchers.127 He told Ms. Tilousi that an ASU student was 
about to defend a dissertation that involved use of tribal blood 
in his research.128 Ms. Tilousi attended the presentation at 
ASU in which the doctoral candidate, Daniel Garrigan, 
reported that DNA from 100 Havasupai blood samples used in 
his research demonstrated that the people had migrated to 
Arizona from Asia.129 This conclusion contradicted the 
Havasupai’s traditional spiritual beliefs that the tribe 
originated in the Grand Canyon.130 Ms. Tilousi stated that “I 
knew we wouldn’t have given this guy or anyone permission to 
do that study. I started to think, ‘How dare this guy challenge 
our identity with our own blood, DNA.’ Then I remembered 
when many of us gave blood years ago for a diabetes project. I 
wondered if this was the same blood.”131 During the question-
and-answer period, Ms. Tilousi challenged the doctoral 
candidate about whether he had obtained permission to use the 
blood for the study. According to Ms. Tilousi, the candidate 
                                                          
 123. Id.  
 124. Havasupai Tribe, 204 P.3d at 1066–67; Rubin, supra note 120. 
 125. Rubin, supra note 120. 
 126. Id.  
 127. Id. Dr. Martin apparently learned in 2002 that ASU researchers had 
continued to use the Havasupai samples after the early diabetes studies had 
failed to find a genetic basis for the prevalence of the disease among the 
Havasupai. He complained to several ASU officials about the research uses 
without the tribe’s consent. Havasupai Tribe, 204 P.3d at 1067. 
 128. Rubin, supra note 120. 
 129. Havasupai Tribe, 204 P.3d at 1067; see also, Rubin, supra note 120. 
 130. Havasupai Tribe, 204 P.3d at 1067; Rubin, supra note 120. 
 131. Rubin, supra note 120. 
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“was really nervous. He said no, not to his knowledge.”132 After 
the presentation, Dr. Martin informed “the Havasupai Tribal 
Council that ASU may have ‘mishandled’ blood samples taken 
as part of the diabetes research project.”133 
Responding to the Havasupai complaints, and with their 
agreement, ASU hired an independent investigator to look into 
the use of the samples.134 The independent investigator found 
conflicting information about the original consent for use of the 
samples.135 A script for an oral discussion of the study included 
references to schizophrenia and depression research, and a 
written consent form described the purpose of the research as 
“to study causes of behavioral/medical disorders.”136 However, 
researchers informed the investigator that they did not think 
the tribe understood their consent to cover research on other 
behaviors, such as schizophrenia and depression.137 However, 
there was agreement that the blood samples were used in 
numerous studies at ASU and other institutions, resulting in at 
least 23 scholarly papers, articles, and dissertations, including 
papers on schizophrenia and “inbreeding” in the Havasupai 
population.138 Apparently, a genetic component to the tribe’s 
diabetes study was proposed and rejected shortly after the 
project began.139 According to reports, Dr. Markow instructed a 
psychiatrist to review tribal medical records for diagnoses of 
schizophrenia, a review which was conducted “alone at night, 
without tribal permission, after the clinic closed.”140 Dr. 
Markow’s research on schizophrenia within the tribe continued 
                                                          
 132. Id.  
 133. Havasupai Tribe, 204 P.3d at 1067. 
 134. Rubin, supra note 120. ASU initially agreed to investigate in April, 
2003. When no information was forthcoming one month later, the Tribe issued 
a “banishment order” for all ASU faculty and employees from the reservation. 
The tribe also informed ASU that it would hold a press conference to discuss 
concerns. At that point, the university offered to hire an external investigator, 
to be selected with the tribal council. The tribe agreed, executing a Joint 
Confidentiality and Cooperative Investigation Agreement. The formal 
investigation was conducted by Stephen Hart, a Phoenix attorney. Havasupai 
Tribe, 204 P.3d at 1067–68. 
 135. Rubin, supra note 120. 
 136. Id. 
 137. Id. 
 138. Id.; see also Havasupai Tribe, 204 P.3d at 1067–68; Rubin, supra note 
120. 
 139. Havasupai Tribe 204 P.3d at 1066–67. 
 140. Rubin, supra note 120. 
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for an additional five years.141 
According to news reports, the title of the consent form 
used with the Havasupai was “Medical Genetics at Havasupai,” 
but the first research protocol submitted to the IRB was 
entitled “Schizophrenia in the Havasupai.”142 It was ultimately 
approved as “Schizophrenia: A Genetic Model,” as were other 
studies entitled “Diabetes in Havasupai” and “Stress Following 
the Havasu Flood.”143 The oral script used during the consent 
process did mention schizophrenia, although not as a specific 
focus of the study.144 It read: “We are conducting research to try 
to identify factors that causes some of the health problems 
experienced by the Havasupai and other Native American 
peoples. Many of these diseases, such as diabetes, 
schizophrenia, depression, are complicated and so we try to 
look at as many factors as possible.”145 The written consent 
stated only that the purpose of the project was to “study the 
causes of behavioral/medical disorders.”146 The Havasupai were 
also promised that “no one’s name will appear on the tubes 
containing the stored blood,” although there were reports that 
at least two labs received blood vials with names on them.147 
Dr. Markow reportedly told the independent investigator that 
written consent meant she and her colleagues could use the 
Havasupai blood for research purposes as they saw fit.148 
2.  The Lawsuit 
In 2004, following the report, the Havaupai sued ASU and 
the researchers, including John Martin and Therese Markow, 
who supervised the doctoral candidate whose presentation 
triggered the dispute, in two separate lawsuits for misuse of 
the biological materials.149 One of the lawsuits involved up to 
                                                          
 141. Id.  
 142. Id.  
 143. Id.  
 144. Id. 
 145. Id.  
 146. Id. 
 147. Id.  
 148. Id.  
 149. Havasupai Tribe v. Ariz. Bd. of Regents, 204 P.3d 1063, 1070 (Ariz. 
Ct. App. 2008). At the time the suit was brought, Dr. Markow had already left 
Arizona State and became director of the University of Arizona Center for 
Insect Science. Lawsuits Against UA Researcher Move to State Court, AP 
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72 Havasupai tribal members (at times) whose blood was used 
in the research; the other was brought by the entire tribe.150 
Both cases were originally filed in state court, were removed to 
federal court by the defendants, where the federal law and 
parens patriae claims were dismissed, and then remanded back 
to state court where they were consolidated.151 The tribe’s 
allegations extended not only to the use of their materials in 
studies they found objectionable, but also to the handling of the 
materials.152 They alleged that ASU researchers erroneously 
destroyed some of the tribal blood and lost other samples 
through transfers within and outside the university.153 Indeed, 
they claimed that some cell lines were lost when freezers failed 
and there were no backups.154 In keeping with their beliefs, the 
tribe wanted all samples returned so that they could bury 
them.155 As Tribal vice chair Dianna Uqualla said when asked 
what the tribe was seeking, other than compensation: 
First, I would like all of the blood returned to us. There are people, 
loved ones, who gave blood and who have passed away. But their 
blood is still out there somewhere, I think. Blood is very important to 
us. We need a ceremony with ASU officials present to bury that 
blood.156 
The tribe also claimed that tribal members had endured 
“severe mental and emotional harm, suffering, fright, anguish, 
shock, nervousness, and anxiety.”157 The Havasupai alleged 
that “ASU’s actions have invaded the personal privacy of 
Havasupai tribal members and the cultural and religious 
privacy of the Havasupai Tribe.”158 Plaintiffs’ counsel claimed 
that: 
ASU has simply left our Clients to worry about the possible uses and 
                                                          
NEWSWIRE, May 5, 2005, [hereinafter Lawsuits].  She took the Havaupai 
samples with her, although tribal members say they were promised that the 
samples would be kept securely at ASU. Rubin, supra note 120. 
 150. Lawsuits, supra note 149; Kerry Fehr-Snyder, ASU Law Prof 
Denounces Collecting Havasupai DNA, ARIZ. REPUBLIC (Phoenix), Mar. 20, 
2004, at 3B. 
 151. Havasupai Tribe, 204 P.3d at 1066 n.1, 1070 n.4. 
 152. Id. at 1069. 
 153. Havasupai Tribe Sues ASU, Board of Regents, AP STATE & LOCAL 
WIRE, March 16. 2004. 
 154. Rubin, supra note 120. 
 155. Id. 
 156. Id.  
 157. Id.  
 158. Havasupai Tribe v. Ariz. Bd. of Regents, 204 P.3d 1063, 1068 (Ariz. 
Ct. App. 2008). 
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locations of their blood samples, the violation of their religious values 
and beliefs, whether these samples have been lost, and whether they 
will continue to be used for additional unauthorized purposes. Many 
of our Clients now fear going to the health clinic, seeking medical 
attention, or providing blood samples for medical diagnosis or 
treatment.159 
ASU and the researchers involved denied any 
wrongdoing.160 Instead, they pointed to the value of the 
research in trying to understand the biological underpinnings 
of the health issues of the Havasupai.161 Dr. Markow’s attorney 
was quoted as saying, “The defendants feel very strongly that 
they didn’t do anything wrong. Whatever kind of 
misunderstanding occurred should never have ended up in a 
lawsuit, and it will have a chilling effect on medical research 
across the country.162 
The trial court entered summary judgment against the 
plaintiffs on the grounds that they did not comply with 
Arizona’s notice of claim statute, which requires claimants to 
include the amount claimed and the facts supporting the 
claimed amount.163 This statutory requirement applies to 
claims against a public entity or employee, with the goal of 
permitting the government entity to “investigate the claim, 
assess its potential liability, reach a settlement prior to 
litigation, budget and plan.”164 The appellate court reversed the 
lower court decision.165 It noted that, “[a]lthough the Tribe’s 
notices do not describe the nature of the injury incurred, 
invasions of privacy relating to tissue samples such as the 
Tribe described in its claim notices naturally give rise to 
subjective personal injury, even when, as here, the samples are 
given voluntarily.”166  The court also noted that other cases had 
recognized claims of violation of privacy when blood samples 
were tested without consent, but  that quantifying the resulting 
injury from them is challenging, given the personal nature of 
                                                          
 159. Id. at 1069 (emphasis removed). 
 160. Lawsuits, supra note 149. 
 161. Id. 
 162. Id.  
 163. Havasupai Tribe, 204 P.3d at 1071. 
 164. Id. at 1072 (citing ARIZ. REV. STAT. ANN. § 12-821.01(A) (2003); Deer 
Valley Unified Sch. Dist. No. 97 v. Houser, 152 P.3d 490, 492 (Ariz. 2007)). 
 165. Id. at 1066. 
 166. Id. at 1076. 
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such tests.167 Thus, the tribe’s claims were revived. There may 
be other procedural hurdles, including consideration of the 
timeliness of their notice of claim that may limit their ability to 
pursue these claims.168 
3.  Implications 
The Havasupai cases give another example of objections 
that some individuals or groups may have to research use of 
their biological materials, as well as the detrimental effect that 
such research uses might have on other research. One tribal 
member, Roland Manakaja, summed up the Havasupai 
complaint by saying, “It was wrong of them to use my blood for 
whatever they used it for without my permission. We were just 
trying to get help for our diabetes, nothing else. How can we 
trust anyone anymore?”169  The Havasupai are not alone; they 
have received support from other Native American 
organizations. For example, the National Congress of American 
Indians (“NCAI”) issued a resolution “Supporting the 
Havasupai Indian Tribe in their Claim Against the Arizona 
Board of Regents Regarding the Unauthorized Use of Blood 
Samples and Research.”170 In it, the NCAI expresses its support 
for “the efforts of the Havasupai Indian Tribe to protect against 
unauthorized genetic research on its Members and other 
indigenous populations” and its opposition to “all unauthorized 
genetic research on Native American populations by . . . any 
individuals or institutions.” 171 Other groups have provided 
financial support for the litigation.172 
Considering the Havasupai claims, ASU law professor 
Gary Marchant has commented that “[a]ll genetic research is 
                                                          
 167. Id at 1076 (citing Norman-Bloodsaw v. Lawrence Berkley Lab., 135 
F.3d 1260, 1269 (9th Cir. 1998); Doe v. High-Tech Inst., Inc., 972 P.2d 1060, 
1064 (Colo. App. 1998)), n.12 (United States v. Comprehensive Drug Testing, 
Inc., 513 F.3d 1085, 1104 (9th Cir. 2008)). 
 168. Id. at 1079. 
 169. Rubin, supra note 120. 
 170. Nat’l Cong. of Am. Indians, Supporting the Havasupai Indian Tribe in 
Their Claim Against the Arizona Board of Regents Regarding the 
Unauthorized Use of Blood Samples and Research, Res. SAC-06-019, 2006 
Cong., 63rd Sess., available at http://www.ncai.org/ncai/resolutions/doc/SAC-
06-019.pdf.    
 171. Id.  
 172. See Press Release, Nat’l Indian Gaming Ass’n, National Indian 
Gaming Association Chairman to Deliver Check to Havasupai Indian Tribe 
(July 15, 2006), available at http://www.indiangaming.org/info/pr/press-
releases-2006/index.shtml. 
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based on an assumption that I’m pretty sure is now crumbling, 
the assumption of no property rights for DNA donors.”173 
Whether or not the law comes to recognize property rights of 
DNA donors, the Havasupai cases and others suggest a need to 
rethink and strengthen the rights of DNA donors over the 
research use of their biological materials. 
E.  COMMON FEATURES OF CASES 
Although the cases discussed here differ factually, they 
demonstrate that people may object to research uses of their 
biological materials, whether or not the specimens are 
identifiable.174 The potential objections are multiple. For 
Moore, it was the use of his materials for commercial purposes 
without his permission. He felt used and betrayed by his 
physician and the other researchers working with him. 175 For 
the Greenbergs and the other families affected by Canavan 
disease, the commercial use was also objectionable. Unlike Mr. 
Moore, the Greenberg families were fully aware that their 
materials were being used – indeed, they actively participated 
in collecting the materials for research use. However, they 
never would have agreed to the use if they had understood that 
other families potentially affected by Canavan disease would 
have to pay to access the medical test they helped make 
possible.176 For the Havasupai, the objections were more 
fundamental. Their materials had been used in research that 
threatened the core of their identity and stigmatized to them 
individually and as a group. Even without these objectionable 
uses, they may still have sued ASU for the additional uses 
because the loss of control of the samples had spiritual 
implications. They may have been willing to give their 
materials for research purposes they recognized as relevant to 
                                                          
 173. Fehr-Snyder, supra note 150. 
 174. Specimens are considered “identifiable” if they can be linked to a 
specific individual either directly (e.g., through information like a name, 
medical record number, or birth date) or indirectly through a coding system. 
Office for Human Research Protections, Department of Health and Human 
Services, Guidance on Research Involving Coded Private Information of 
Biological Specimens, 
http://www.hhs.gov/ohrp/humansubjects/guidance/cdebiol.htm (last visited 
Oct. 30, 2008) [hereinafter Guidance]. 
 175. See supra Section II.a. 
 176. See supra Section II.b. 
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the health and well-being of their community, despite the 
spiritual implications. Perhaps they did not realize that their 
biological materials would not be fully consumed in that 
research. However, once it became clear that those materials 
remained, they expressed their wish to control the use and 
disposal of their biological materials. Although the reasons may 
be different, the plaintiffs who supported Dr. Catalona 
appeared to share some of the Havasupai’s desire for 
controlthey wanted to be sure that their materials were being 
used for the work they supported, and by a researcher in whom 
they had confidence. 
How important did the plaintiffs consider their interests in 
their biological materials? So important that they were willing 
to bring suit, with all the financial, emotional, and time 
burdens involved in litigation, and despite the long odds of 
winning.177 In each case, the plaintiffs faced substantial 
hurdles in even bringing their claims. All of the cases have 
been decided on the pleadingson motions to dismiss or 
summary judgment.178 In each case, the court substantially 
narrowed the potential causes of action.  As will be discussed 
infra, their cases may have been hampered, in part, because of 
how research involving biological materials is treated within 
the human subjects research regulatory framework. 
III.  HUMAN BIOLOGICAL MATERIALS WITHIN THE 
HUMAN SUBJECTS RESEARCH REGULATORY 
FRAMEWORK 
To understand how research involving biological materials 
                                                          
 177. Others have expressed concern or dissatisfaction with how biological 
materials have been used in research. See, e.g., Jill Jensen, Lawsuit Filed Over 
Collection of Infant DNA, NBC ACTION NEWS, March 12, 2009, available at 
http://www.nbcactionnews.com/content/aroundtheweb/story/Lawsuit-Filed-
Over-Collection-of-Infant-DNA/61nyl0_9nEi-Eetup_WS1w.cspx (describing 
lawsuit filed against Minnesota state health department for collecting and 
storing blood and DNA from infants without consent). Requests for DNA from 
historical figures, such as Presidents Jefferson and Lincoln, have been subject 
to debate. Edward Colimore, Lincoln’s ‘Shroud of Turin’, PHILA. INQUIRER, 
April 13, 2009, available at http://garmuslib.org/pdf/Lincoln.pdf; James Dao, A 
Family Get-Together of Historic Proportions, N.Y. TIMES, July 14, 2003, at A9.  
In addition, patients have brought suit against Myriad Genetics, challenging 
the product of research on DNA samplesthe patent on the BRCA1 and 
BRCA2 gene. John Schwartz, Cancer Patients Sue Testing Company and 
Government Over Gene Patents, N.Y. TIMES, May 13, 2009, at A16. 
 178. The Havasupai case is the only case still pending, after the tribe’s 
claims were revived by the appellate court. 
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is treated within the human subjects research regulatory 
framework, it is first necessary to understand that framework.  
This section begins with a description of the Common Rule and 
the exceptions under that rule.  It next examines how scientific 
developments are challenging the underlying assumptions that 
have permitted biological materials to be used under the 
exceptions to the Common Rule requirements. 
A.  THE COMMON RULE 
Beginning in 1974, the federal government instituted 
regulations to govern the conduct of research involving human 
subjects.179  The regulations apply to research conducted by the 
federal government or supported by the federal government 
(e.g., through contract or grants).  Universities and other 
institutions holding a federalwide assurance may agree to 
apply the regulations to non-federally funded research, as 
well.180 Sixteen government agencies have adopted the 
Common Rule governing human-subjects research, which 
differs in only relatively minor ways from the separate Food 
and Drug Administration regulations.181 
                                                          
 179. ROBIN LEVIN PENSLAR, PROTECTING HUMAN RESEARCH SUBJECTS: 
INSTITUTIONAL REVIEW BOARD GUIDEBOOK xviiixxiv (1993). 
 180. The regulations specify to what they apply at 45 C.F.R. § 46.101 
(2008). In addition, institutions that engage in research that is covered by the 
regulations (i.e., universities and other institutions receiving federal money to 
conduct research) must provide assurance to the Department of Health and 
Human Services that they will comply with the provisions of those 
regulations. 45 C.F.R. 46.103 (2008). The current form of that assurance is 
called the “federalwide assurance.” Its name indicates that it is approved for 
federalwide use, i.e., other federal departments or agencies that subscribe to 
the Common Rule may rely on it. The federalwide assurance applies to all 
non-exempt human subjects research that is conducted or funded by a federal 
department or agency that has adopted the Common Rule, and institutions 
may voluntarily extend its coverage to all human subjects research conducted 
at the institution. Office for Human Research Protections, Department of 
Health and Human Services, Federalwide Assurance Frequently Asked 
Questions, http://www.hhs.gov/ohrp/FWAfaq.html [hereinafter Federalwide] 
(last visited Oct. 21, 2009). Even if institutions extend the coverage of the 
federal regulations, there are important gaps in coverage (especially research 
by private companies that is not otherwise covered by the FDA regulations). 
Meslin & Quaid, supra note 2, at 230. 
 181. The Common Rule refers to 45 C.F.R. pt. 46, subpart A, issued by the 
Department of Health and Human Services. Additional signatories include the 
Department of Agriculture, Department of Commerce, Department of Defense, 
Department of Education, Department of Energy, Department of Housing and 
Urban Development, Department of Justice, Department of Veterans Affairs, 
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The federal regulations apply to all research that involves 
human subjects.182  “Research” is defined as a “systematic 
investigation . . . designed to develop or contribute to 
generalizable knowledge.”183  A “human subject” is defined as a 
“living individual about whom an investigator (whether 
professional or student) conducting research obtains (1) Data 
through intervention or interaction with the individual, or (2) 
Identifiable private information.”184 Human-subject research 
within the scope of the regulations must be reviewed and 
approved by an Institutional Review Board (IRB) before it can 
begin.185  Consent to participate is also required, and the 
regulations specify information that must be disclosed to the 
                                                          
Department of Transportation, Consumer Product Safety Commission, 
Environmental Protection Agency, Agency for International Development, 
National Aeronautics and Space Administration, National Science 
Foundation. Federalwide, supra note 180. The Central Intelligence Agency 
must comply with the Common Rule, as well as the special protections for 
pregnant women and fetuses, prisoners, and children under Executive Order 
12333. Id. The Food and Drug Administration regulations are substantially 
similar to the Common Rule. The FDA regulations apply to all research 
involving products regulated by the FDA. Both the Common Rule and the FDA 
regulations have exceptions to informed consent, but the circumstances are 
different; the FDA authorizes emergency research under specified 
circumstances and does not recognize the waiver of consent available under 45 
C.F.R. 46.116 (c) and (d). See 21 C.F.R. § 50.1–3 (2009); see also Guidance for 
Institutional Review Boards and Clinical Investigators, 19988 Update, 
http://www1.va.gov/oro/apps/compendium/Files/appendixe.htm (last visited 
Feb. 15, 2010). 
 182. 45 C.F.R.§ 46.101 (2008).  
 183. 45 C.F.R. § 46.102(d) (2008).  
 184. According to the regulations, “[i]ntervention includes both physical 
procedures by which data are gathered (for example, venipuncture) and 
manipulations of the subject or the subject’s environment that are performed 
for research purposes. “Interaction” includes communication or interpersonal 
contact between investigator and subject. Private information includes 
information about behavior that occurs in a context in which an individual can 
reasonably expect that no observation or recording is taking place, and 
information which has been provided for specific purposes by an individual 
and which the individual can reasonably expect will not be made public (for 
example, a medical record). Private information must be individually 
identifiable (i.e., the identity of the subject is or may readily be ascertained by 
the investigator or associated with the information) in order for obtaining the 
information to constitute research involving human subjects.” 45 C.F.R. § 
46.102(f) (2008). 
 185. 45 C.F.R. § 46.101  (requiring IRB approval); 45 C.F.R. § 46.107 (2008) 
(establishing requirements for IRB composition); 45 C.F.R. § 46.109 (2008) 
(outlining IRB review of research); 45 C.F.R. § 46.111 (2008) (setting criteria 
for IRB approval of research). 
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There is no question that research in which tissue samples 
are obtained prospectively from living people specifically for 
research falls within the definition of human subjects research.  
Whether the material is obtained by blood draw, tissue biopsy, 
or cheek swab, it involves an “intervention or interaction with” 
a living individual.  Nevertheless, there are several ways in 
which research involving preexisting specimens may not 
constitute “human subjects research.” According to guidance 
from the Office for Human Research Protections (OHRP), 
research involving only coded specimens187 does not involve 
human subjects if: 
(1) the private information or specimens were not collected 
specifically for the currently proposed research project through an 
interaction or intervention with living individuals; and 
(2) the investigator(s) cannot readily ascertain the identity of the 
individual(s) to whom the coded private information or specimens 
pertain because, for example: (a) the investigators and the holder of 
the key enter into an agreement prohibiting the release of the key to 
the investigators under any circumstances, until the individuals are 
deceased (note that the HHS regulations do not require the IRB to 
review and approve this agreement); (b) there are IRB-approved 
written policies and operating procedures for a repository or data 
management center that prohibit the release of the key to the 
investigators under any circumstances, until the individuals are 
deceased; or (c) there are other legal requirements prohibiting the 
release of the key to the investigators, until the individuals are 
deceased.188 
                                                          
 186. 45 C.F.R. § 46.111 (2008) (requiring informed consent from research 
participants); 45 C.F.R. § 46.116 (2008) (providing requirements for informed 
consent). 
 187. When specimens are coded, the specimens are given a unique 
identifier (code). Ideally, the code is unrelated to identifying information (e.g., 
name, medical record number, birth date), making it difficult, if not 
impossible, to reconnect the specimen the individual donor without access to 
the list linking the code to the identifying information. See NBAC, supra note 
2, at 17. 
 188. Office for Human Research Protections, Department of Health and 
Human Services, Guidance on Research Involving Coded Private Information 
of Biological Specimens, 
http://www.hhs.gov/ohrp/humansubjects/guidance/cdebiol.htm [hereinafter 
Guidance] (last visited Oct. 30, 2008). It is important to note, however, that if 
the investigator somehow obtains individually identifiable information during 
the course of the study, the research would then involve human subjects and 
be subject to IRB review, unless determined to be exempt. Id. The guidance 
considers specimens “coded” when “(1) identifying information (such as name 
or social security number) that would enable the investigator to readily 
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Example (a) is often called the “honest broker” 
agreement.189 Using this type of arrangement, one investigator 
might share specimens she has already collected with another 
investigator.  Because the second investigator did not obtain 
the specimens through interaction or intervention with the 
specimen donors and does not—and because of the agreement, 
cannot—receive personally identifiable information about the 
donors, her research does not qualify as “human subjects 
research.”  A more efficient approach to specimen sharing is to 
create a central repository that houses the materials and takes 
responsibility for ensuring they are used in conformance with 
the regulatory requirements.190  Example (b) addresses this 
approach.  Like the honest broker approach, there are 
agreements that prohibit release of identifiable information.  
However, the agreements protecting the identifiable 
information apply to any investigator who seeks to use the 
repository specimens rather than being negotiated on an ad hoc 
basis. 
Research that constitutes “human subjects research” may 
still be exempt from the federal regulations and, thus, from 
IRB review.  Research involving existing specimens may be 
exempt if they are “publicly available or if the information is 
recorded by the investigator in such a manner that subjects 
cannot be identified, directly or through identifiers linked to 
the subjects.”191  The federal government makes some 
specimens that it collects, such as specimens collected through 
the National Health and Nutrition Examination Survey 
(NHANES) study, available to qualified researchers.192  
                                                          
ascertain the identity of the individual to whom the private information or 
specimens pertain has been replaced with a number, letter, symbol, or 
combination thereof (i.e., the code); and (2) a key to decipher the code exists, 
enabling linkage of the identifying information to the private information or 
specimens.” Id. 
 189. For a fuller description of the “honest broker,” see Rajiv Dhir et al., A 
Multidisciplinary Approach to Honest Broker Services for Tissue Banks and 
Clinical Data: A Pragmatic and Practical Model, 113 CANCER 1705 (2008); 
Institutional Review Board, University of Pittsburgh, Honest Broker, 
http://www.irb.pitt.edu/exempt/honestbroker.htm (last visited Oct. 21, 2009). 
 190. Efficiency comes from combining materials, resources (such as 
freezers and computers), and personnel. Many institutions have encouraged 
investigators to use central resources for biological materials they collect in 
order to take advantage of these efficiencies and to exert greater control over 
the use of such materials (and, thus, hopefully to avoid misuse). 
 191. 45 C.F.R. § 46.101(b)(4) (2008). 
 192. ENVTL. PROT. AGENCY, HANDBOOK FOR USE OF DATA FROM THE 
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Although the specimens may be coded, researchers are not 
provided with identifiers.  Finally, some specimens may be 
available through companies that provide specimens for a fee.  
All of these sources of specimens would qualify as “publicly 
available,” and, thus, research using them may be exempt from 
the federal regulations.  In addition, the researcher can fall 
within the exemption by taking steps to avoid having 
identifiers.  For example, even if specimens have individually 
identifiable information on them, if the researcher records 
information without the identifiers (e.g., by code not linked to 
the identifiers and to which the key is not retained), the 
research may be exempt.  Similarly, the researcher can strip 
identifiers from the sample so that the research can qualify as 
exempt.  The regulations specifically refer to pathological and 
diagnostic specimens in this exemption.  Thus, the regulations 
clearly contemplate that materials collected for clinical 
purposes may be used for research and may fall outside the 
regulations governing human subjects research.  Importantly, 
for all of these examples, it is assumed that the specimens were 
collected for some other purpose (whether for research or 
clinical purposes) rather than the current research.  Otherwise, 
there would be an interaction or intervention with a living 
subject that would put the research within the scope of the 
federal research regulations. 
Finally, even non-exempt human subjects research may be 
conducted without consent if it meets certain criteria.  
Specifically, research may be conducted without consent if: 
(1) the research involves no more than minimal risk to the subjects; 
(2) the waiver or alteration will not adversely affect the rights and 
welfare of the subjects; 
(3) the research could not practicably be carried out without the 
waiver or alteration; and 
(4) whenever appropriate, the subjects will be provided with 
additional pertinent information after participation. 193 
A researcher may wish to conduct research under a waiver 
of consent described above, for example, when she wishes to use 
identifiable specimens for a purpose not addressed when the 
participant consented to the donation. There is no additional 
                                                          
NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEYS (NHAHES): A 
GOLDMINE OF DATA FOR ENVIRONMENTAL HEALTH ANALYSES  ii (2003) 
[hereinafter EPA].  
 193. 45 C.F.R. § 46.116(d)(1)–(4) (2008). 
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physical risk to subjects because the materials have already 
been collected. Other risks likely can be minimized by attention 
to confidentiality protections.  To meet the requirements under 
the regulations for the waiver that the research would not be 
“practicable” without the waiver, the researcher probably 
would need to be using a very large number of specimens that 
were collected some time ago. 
As the discussion demonstrates, much research involving 
human biological materials could be undertaken without the 
knowledge or consent of the individuals who donated the 
materials. 
B.  SCIENTIFIC CHALLENGES TO THE COMMON RULE APPROACH 
The Common Rule approach to research involving human 
biological materials rests on the assumption that biological 
materials can be effectively deidentified.194  While undoubtedly 
true when the Common Rule was adopted, recent scientific 
developments raise questions about the validity of our 
assumption about our ability to deidentify DNA.195  As McGuire 
and Gibbs explain, scientists have been challenging our 
assumptions about deidentification for at least five years.196  If 
a person has access to only seventy-five single-nucleotide 
polymorphisms (SNPs) from an individual, that person can be 
identified.197  Genome-wide association studies generate 
thousands more SNPS for each individual.198  As McGuire and 
Gibbs note, reidentification from a collection of SNPs requires 
an identified sample or “reference sample”.  But as DNA 
databases proliferate and those data are shared among 
researchers, reference samples will be more available and 
reidentification will become more likely.199  Because they 
                                                          
 194. Specimens that have been “deidentified” have had identifiers or codes 
removed from them. 
 195. Meslin & Quaid, supra note 2, at 230. 
 196. Amy L. McGuire & Richard A. Gibbs,  No Longer De-Identified, 312 
SCI. 370, 370 (2006). 
 197. Zhen Lin et al., Genomic Research and Human Subject Privacy, 305 
SCI. 183, 183 (2004). 
 198. McGuire & Gibbs, supra note 196, at 370. 
 199. Id. Potential reference sources include DNA samples collected by the 
military, law enforcement, researchers, and health care providers. William W. 
Lowrance & Francis S. Collins, Identifiability in Genomics Research, 317 SCI. 
600, 600 (2007). Such databases may be quite comprehensive and are 
increasing. For example, many states collect, and may retain at least for some 
period, blood spots from newborn genetic screening. Jensen, supra note 177; 
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perceived greater risk from genome-wide association studies 
and corresponding public release of data than previously 
acknowledged, McGuire and Gibbs have recommended that 
such studies be brought within the human subjects research 
regulations.200  McGuire and Gibbs and other commentators 
have not sought to prohibit sharing of genomic datathe 
science is valuable and advancements depend on such sharing.  
However, they have brought to light challenges to our 
underlying assumptions about this type of research that 
suggest greater oversight may be needed.201 
Other research strengthens the concerns expressed by 
McGuire and Gibbs.  In a recent article, scientists 
demonstrated a statistical method for resolving individual 
genotypes within a mix of DNA samples or datasets containing 
aggregate single-nucleotide polymorphisms.202  This article 
                                                          
Nora Macaluso, State Setting Up ‘Biobank’ for Samples of Newborns’ Blood for 
Disease Research, 8 MED. RES. L. & POL’Y REP. 432, 432 (2009). For a number 
of years, the federal government has collected DNA from those convicted of 
federal crimes in a DNA database used for law enforcement purposes. In 2008, 
Congress authorized the federal government to collect DNA samples from 
anyone arrested by a federal law enforcement agency and all foreigners who 
are detained, along with DNA collected from those convicted of federal crimes. 
States have also been collecting DNA samples from those convicted of, charged 
with, or arrested for crimes. The federal government also collects DNA from 
all military personnel in a separate database. Solomon Moore, F.B.I. and 
States Vastly Expanding Databases of DNA, N. Y. TIMES, Apr. 19, 2009, at A1. 
Commercial sources might also serve as a reference database; numerous 
companies have been offering genetic testing to individuals for a variety of 
purposes (e.g., health, genealogy research), and decreasing prices make such 
testing more accessible. Risks of Sharing Personal Genetic Information Online 
Need More Study, Stanford Bioethicists Say, BUS. WIRE, June 5, 2009, 
available at 
http://www.businesswire.com/portal/site/home/permalink/?ndmViewId=news_
view&newsId=20090605005014&newsLang=en; Bolnick et al., supra note 11, 
at 399. Indeed, the cost of whole genome sequencing has dropped considerably 
since the human genome was first completed. W. Gregory Feero, et al., The 
Genome Gets Personal—Almost, 299 JAMA 1351, 1351 (2008); Lisa M. Krieger, 
Scientists: Long-Promised ‘$1,000 Gene Sequence’ Less Than Two Years Off, 
SAN JOSE MERCURY NEWS, June 12, 2009, available at 
http://www.geneticsandsociety.org/article.php?id=4717; Brian Dolan, Illumina 
Demos Concept iPhone App for Genetic Data Sharing, MOBIHEALTHNEWS, 
June 10, 2009, available at http://mobihealthnews.com/2658/illumina-demos-
concept-iphone-app-for-genetic-data-sharing. 
 200. McGuire & Gibbs, supra note 196, at 371. 
 201. Id. at 37071; Lowrance & Collins, supra note 199, at 60001. 
 202. Lowrance & Collins, supra note 199, at 601; Nils Homer et al., 
Resolving Individuals Contributing Trace Amounts of DNA to Highly Complex 
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prompted the NIH (among others) to remove aggregate data 
obtained from genome-wide association studies from its open 
access databases.203  The NIH is now reconsidering its policies 
on data sharing for such research and is urging others to do the 
same.204  Such reconsideration of policy should involve OHRP, 
IRB members and staff, and donors of research materials. 
IV.  WHAT EMPIRICAL DATA TELL US ABOUT RESEARCH 
WITH HUMAN BIOLOGICAL MATERIALS 
Although the federal regulations provide numerous ways to 
conduct research with biological samples without the explicit 
permission of donors, empirical data suggest that this approach 
is not fully embraced within the research community. 
A.  IRB CHAIRS STUDY205 
Along with colleagues, I conducted an interview study with 
IRB Chairs to evaluate their perspectives on ethical issues in 
research involving stored specimens.  Our goal was to identify 
potential barriers to such research, as well as solutions for 
overcoming these barriers. 
1.  Methods 
We asked Chairs to respond to a hypothetical study that 
                                                          
Mixtures Using High-Density SNP Genotyping Microarrays, 4 PLOS GENETICS 
1, 7 (2008), available at 
http://www.plosgenetics.org/article/info%3Adoi%2F10.1371%2Fjournal.pgen.1
000167. 
 203. Jennifer Couzin, Whole-Genome Data Not Anonymous, Challenging 
Assumptions, 321 SCI. 1278, 1278 (2008); Elias A. Zerhouni & Elizabeth G. 
Nabel, Letter to the Editor, Protecting Aggregate Genomic Data, 322 SCI. 44, 
44 (2008). 
 204. Zerhouni & Nabel, supra note 203, at 44. 
 205. The details of the study may be found in Leslie E. Wolf et al., IRB 
Chairs’ Perspectives on Genomics Research Involving Stored Biological 
Materials: Ethical Concerns and Proposed Solutions, 3 J. EMPIRICAL RES. ON 
HUM. RES. ETHICS 99, (2008). The study was funded by the National Institute 
of Mental Health (1 RO1 MH064696). The principal investigator was Joseph 
Catania. Other senior members of the research team were Bernard Lo, M. 
Margaret Dolcini, and Lance M. Pollack. The study was approved by IRBs for 
the University of California San Francisco and the Henne Group (which 
conducted the interviews). The Chairs were recruited from a national sample 
of IRBs that review mental health-related research protocols. We interviewed 
a total of 85 Chairs, consisting of 32 Chairs from the 100 institutions receiving 
the most NIH funding in fiscal year 2002 and 53 Chairs from all other 
institutions. We had an overall participation rate of 65%. Fifty-five Chairs 
received the DNA scenario. 
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proposed to identify a genetic marker for schizophrenia using 
specimens previously collected for Alzheimer’s research.206  The 
hypothetical study was developed to contain sufficient detail to 
“ring true” to IRB Chairs, while also raising ethical topics 
identified in the literature as important.  The four ethical 
topics embedded in the scenario included consent, 
confidentiality, identifiability of specimens, and recontact of 
participants.  Because we wanted their considered reflections, 
we sent Chairs the hypothetical study two weeks prior to their 
interview and asked them to review it in advance of their 
interview.  The interview was conducted using a semi-
structured interview guide.207  Chairs were first asked what 
human subjects concerns they had with the hypothetical study.  
They then were asked what solutions they could offer to 
address the concerns they had raised.  Finally, they were asked 
to respond to both ethical concerns and potential solutions 
identified in the literature and rate their importance and 
helpfulness, respectively, on a four-point scale.208  Finally, the 
Chairs were asked some general questions about their 
approaches to difficult protocols. 
The interviews were recorded and transcribed verbatim.  
We then used the transcriptions to code for predetermined 
themes and analyze them. 
2.  Study Results 
The study was set up to raise questions about whether the 
original consent covered the proposed new research use of the 
                                                          
 206. Each Chair received two out of three hypothetical studies to review. 
The topics of the three hypothetical studies included: (1) DNA analysis of 
stored samples and review of medical records, (2) withdrawal of medication for 
psychiatric illness in children, and (3) a survey of mental health problems 
among homeless persons. Id. at 100.  Only the DNA study is relevant to this 
discussion. 
 207. “Semi-structured” means that there were specific questions that were 
to be asked of all respondents, but that there was also flexibility built into the 
interview guide, including suggested probes for following up. This approach 
ensures that the same material is covered with different respondents, but also 
permits for a full exploration of the Chairs’ perspectives in a more natural 
conversation. 
 208. When asked to rate the importance of an issue, the 4-point scale was 
very important, somewhat important, somewhat unimportant, and very 
unimportant. When asked to rate the helpfulness of a suggestion, the 4-point 
scale was very helpful, somewhat helpful, somewhat unhelpful, and very 
unhelpful. 
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specimens.  The purpose of the hypothetical study was “to 
identify candidate genes for schizophrenia through DNA 
analysis of stored blood samples” with the goal of ultimately 
“identifying new targets for innovative drug therapies and to 
better predict who is at risk for schizophrenia.”209  However, 
the research will use “blood samples and clinical records 
(including detailed mental health interviews and family 
histories) . . . from a community-based sample of 3,000 people 
over age 60 who volunteered for a study of risk factors for 
dementia . . . completed 5 years ago.”210  The Chairs were told 
that “[t]he participants authorized researchers in the original 
study to carry out additional studies ‘related to the research 
topic,’” but that “[t]he consent form for the original study did 
not mention subsequent uses of stored materials in other 
research studies or other future analyses of data in the clinical 
records.”211  The IRB had previously approved DNA analyses on 
apolipoprotein E as a risk factor for Alzheimer’s.  To set up the 
issue of potential waiver of consent, the hypothetical study also 
included a claim that “it would not be feasible to go back to all 
participants in the original study to seek their authorization for 
the use of their samples and clinic records.”212 
Eighty-seven percent of the Chairs said that whether the 
original consent covered the proposed new use of the biological 
specimens was an ethical concern in the hypothetical study.  
Moreover, those who raised the issue overwhelmingly (92%) 
concluded that the consent for the original study did not cover 
the proposed schizophrenia research.213  In support of their 
conclusions, Chairs variously noted that schizophrenia is “quite 
different than dementia,” that such use would “stretch the 
original agreement . . . too far,” and that allowing the use 
“could undermine the trust that subjects have in 
researchers.”214  Their concerns about the apparent lack of 
consent for the proposed new use of the biological materials 
also was evidenced by the number of Chairs who indicated that 
either they or their IRB (or both) would not approve the 
protocol because of the lack of consent.  Although they were not 
specifically asked whether they would approve it, one-third of 
                                                          
 209. Wolf et al., supra note 205, at 111. 
 210. Id. 
 211. Id. 
 212. Id. 
 213. Id. at 102. 
 214. Id.  
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chairs who raised questions about scope of consent indicated 
that those concerns would preclude approval.  One Chair 
summed it up succinctly as being “kind of a show stopper.”215 
At least some of these Chairs were familiar with the 
regulatory exceptions that permit some uses of biological 
materials without consent.  Eighty-three percent of Chairs 
suggested removing identifiers as a solution to conducting 
research without explicit consent.216  Similarly, 31% of Chairs 
discussed the possibility of waiving consent as a way of 
resolving the consent issue.  Nevertheless, they expressed some 
reservations about using these approaches.  For example, with 
respect to waiver, all the Chairs expressed concerns about the 
appropriateness of waiver in the hypothetical study because the 
researchers could identify the donors of specimens, so that 
obtaining consent was not “impracticable” as the regulations 
require, and/or because the research present more than 
minimal risk.217  As one chair commented, “it’s a major concern 
to use convenience as a way of avoiding doing [the research] 
properly”i.e., by obtaining consent for the research use.218  
This may, in fact, be a misinterpretation of the regulations,219 
which leaves open the possibility that it is impracticable to 
obtain consent from a large number of donors even if the 
researcher knows their identities. Nevertheless, the comment 
demonstrates the Chairs’ strong preference for consent to 
possible future uses.  Indeed, Chairs most commonly suggested 
obtaining consent for the proposed new use as a way of 
avoiding the ethical problems they identified.  Chairs suggested 
that this could be achieved either by “starting over” by 
obtaining new samples from new participants with consent, 
contacting the original participants to ask them to consent to 
the proposed new use, or improving the discussion of future 
uses of materials in the initial consent so that such problems 
would be avoided.220  This last suggestion would be impossible 
to implement in the hypothetical study where materials 
already have been collected. 
                                                          
 215. Id.  
 216. Id. at 103. 
 217. Id. 
 218. Id. 
 219. For regulation text, see supra test accompanying notes 178193. 
 220. Id. at 105. 
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B.  INVESTIGATOR PRACTICES STUDY 
In this study, colleagues and I studied investigator 
protocols and consent forms to determine how they address 
common ethical issues in research involving stored biological 
materials. 
1.  Methods221 
We requested study documents from two sources: (1) 
federally funded general and pediatric clinical research centers 
(CRCs) and (2) federally funded Specialized Programs of 
Research Excellence (SPOREs) at the medical schools and 
research institutions that receive the most NIH funding.222  
NIH funding is an indicator for research volume; thus, we 
expected these institutions would have sufficient documents for 
our purposes.  In addition, we expected that researchers using 
these resources would most likely reflect the standards in the 
field because CRCs and SPOREs are intended to set standards 
of high quality research and CRCs and SPORES conduct their 
                                                          
 221. Details concerning the study, including the methods and results, were 
originally reported in Leslie E. Wolf et al., Genetic Research with Stored 
Biological Materials: Ethics and Practice, 40 IRB: ETHICS & HUM. RES. 7, 718 
(forthcoming March 15, 2010). This study was funded by the National Cancer 
Institute (R01CA117868). Leslie Wolf was the principal investigator. Other 
members of the research team included Charles E. McCulloch and Timothy A. 
Bouley. 
 222. CRCs are federally-funded centers designed to provide research 
infrastructure, including space, equipment, laboratory facilities, and access to 
experts in critical disciplines, to conduct sophisticated patient-oriented 
research. The general CRCs and pediatrics CRCs differ in terms of the 
populations they serve. COMM. ON ADDRESSING CAREER PATHS FOR CLINICAL 
RESEARCH , INST. OF MED., CAREERS IN CLINICAL RESEARCH: OBSTACLES AND 
OPPORTUNITIES 6785 (William N. Kelley & Mark A. Randolph eds., 1994). 
SPOREs are federally-funded programs designed to promote novel, 
interdisciplinary cancer research, with the specific goal of moving basic 
research findings from the laboratory to clinical settings. National Cancer 
Institute, Specialized Programs of Research Excellence, 
http://spores.nci.nih.gov/index.html (last visited Oct. 17, 2009). We recruited 
CRCs and SPOREs sequentially based on their NIH funding ranking (fiscal 
year XXXX), starting from the institutions that received the most funding. 
Some institutions had more than one CRC or SPORE. For CRCs, we selected 
either the main campus CRC or the one with most NIH funding. If a CRC 
declined to participate, did not respond, or withdrew from our study after 
agreeing to participate, we replaced it with the next-largest CRC at the same 
institution (if one existed). Because we found no readily accessible information 
about the relative size of SPOREs, we randomly selected one SPORE within 
eligible institutions with multiple SPORES. If all CRCs or SPOREs at a 
particular institution declined to participate, we invited the next-highest-
funded institution on the NIH list. 
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own review for scientific merit and regulatory compliance of 
research protocols that use their resources, in addition to any 
IRB review.223 
The request for study documents was made directly to the 
director of the CRC or the SPORE.224  To be eligible for study 
inclusion, they had to have indicated that the study (1) used 
stored biological material for genetic (DNA) testing; (2) stored 
biological materials for future genetic (DNA) testing, or (3) 
stored biological materials for future research where future 
genetic (DNA) testing was neither explicitly contemplated nor 
prohibited.  With our assistance, CRCs and SPOREs identified 
potentially eligible studies and requested permission from the 
investigators to share their study documents with us.225  All 
documents were redacted to remove information identifying 
participants and assigned a code that identified documents 
from the same institution and from the same investigator so 
that we could account for clustering in our statistical 
analyses.226 
We coded the documents according to pre-established 
topics, focusing on issues of consent, control over specimens, 
confidentiality, and disclosure of research results to 
participants,  that have been identified as important in the 
ethics literature, for analysis.227 
2.  Results 
We ultimately received 139 studies (115 from CRCs and 24 
from SPOREs) from 17 general CRCs, 3 pediatric CRCs, and 19 
                                                          
 223. Wolf et al., supra note 221. 
 224. We requested eight document sets from CRCs and two from SPOREs. 
We sought more documents from CRCs because they offered a broader range 
of research topics; SPOREs’ research is limited to cancer. Despite the more 
limited research topic, SPOREs provided essential data because they include a 
biorepository as a core function and much cancer research relies on stored 
biological materials. 
 225. Although we used only documents from which all identifying 
information (e.g., name of investigators, institutions, and experimental drugs) 
were removed and, thus, consent may not have been required under the 
federal regulations, we elected to notify investigators of the study and request 
their permission to include their documents in our study. We did not 
communicate directly with the investigators and documentation of consent 
was waived to protect their confidentiality. Id. 
 226. Id.  
 227. Id.  
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SPOREs across the country.228 We found that investigators 
overwhelmingly relied on consent when using biological 
materials for research, even for those twelve studies that used 
materials that had been collected previously and which may 
not have fallen within the federal regulations governing human 
subjects.229 In addition, when collecting new specimens, 75% of 
investigators used consent forms that allowed participants to 
select among different options regarding future use of their 
specimens, and the majority of investigators limited future 
research to certain conditions or uses in their consent forms.230 
Because we studied only the documents and did not interview 
investigators, we cannot determine whether investigators 
preferred these approaches or whether IRBs, CRCs, or SPOREs 
required these approaches.  Regardless of who determined the 
approach, our data suggest that actual practices in research 
involving stored biological materials  put more weight on the 
donors’ interests in controlling the use of their own biological 
materials than the regulations suggest is necessary. This is 
despite the fact that doing so may limit future research. 
Despite this apparent recognition of donors’ interests in 
deciding when and how their biological materials may be used 
in research, we found nine studies that permitted investigators 
to continue to use biological materials in research after a 
participant requested to withdraw from the study, provided the 
researchers removed identifiers. We found this approach 
ethically and legally problematic. Although the regulations and 
OHRP guidance permit the use of biological materials without 
identifiers to be used in research without consent under some 
circumstances,231 the underlying rationale for those exceptions 
do not apply in cases where the participant asks to withdraw 
from study participation. Participants have a right to withdraw 
from research at any time.232 The Catalona case establishes 
that the right to withdraw from research does not mean that 
participants have the right to have their materials returned to 
                                                          
 228. Id. The overall response rate was 52% (39 of 75 eligible institutions). 
 229. These twelve studies included seven using only materials that had 
been previously collected and five that used both existing materials and 
prospectively collected materials. Id. at tbl.2. The federal regulations do not 
apply to unidentified samples, exempt previously collected materials under 
certain conditions, and permit waiver of consent. See supra Section III. 
 230. Wolf et al., supra note 221. 
 231. See 45 C.F.R. § 46.101(b) (2008); 45 C.F.R. § 46.116 (2008); Guidance, 
supra note 174. 
 232. 45 C.F.R. § 46.116(a)(8). 
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them.233 However, for research that includes storing biological 
materials for future use, for the right to be withdraw to be 
meaningful, research participants must be able to ask to have 
their materials withdrawn from further research use. The 
approach to withdrawal that allows research to continue on 
deidentified specimens misconstrues the regulatory 
requirements and mistakenly understands the only potential 
objections to continued use to be ones of confidentiality. To use 
the materials after a participant requests to withdraw violates 
the participant’s wishes and thus also violates both the ethical 
principles governing human subjects research and the federal 
regulations that incorporate those principles. 
C.  RESEARCH PARTICIPANTS’ STUDIES 
The other significant, and perhaps most important, 
stakeholder group in this process is the donors of biological 
materials. The legal cases reviewed above demonstrate that at 
least some individuals object to certain uses of their biological 
materialsenough to bring a lawsuit. Research data provide 
further evidence that some individuals object to some uses of 
their biological materials. 
A number of research groups have sought to understand 
public preferences regarding research involving stored 
biological materials. Their studies have targeted different 
populations within and outside the United States using a 
variety of methods.234 Using meta-analysis to evaluate the data 
from these diverse studies to reach broader conclusions, 
Wendler found that most people want to be asked whether 
their materials can be used in research. At the same time, most 
(17 out of 20) studies found that a significant majority of people 
(at least 80%) would donate their materials for research.  
Wendler’s analysis suggests that public opinion and 
preferences are more consistent with IRB and investigator 
practices than with the legal approaches discussed previously; 
that is, the majority of people do not want their biological 
materials used for research without their consent, even though 
                                                          
 233. E.g., supra Section II.c. 
 234. E.g., David Wendler, One-Time General Consent for Research on 
Biological Samples, 332 BRIT. MED. J. 544, 544 (2006) (citing to and 
summarizing thirty studies published in English that report the “views of 
individuals on consent for research with human biological samples.”). 
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they are generally willing to contribute when asked. 
However, Wendler’s analysis may not fully take into 
account the interests of minority groups, a limitation he 
explicitly acknowledges: “one-time general consent [in which 
research participants are asked to agree to donate their 
materials for all future, unspecified research] may not be 
consistent with the values of some groups. Future research 
should evaluate its acceptability for groups, such as Native 
Americans, and areas of the world, such as Latin America, that 
are not included in the present data.”235 Again, case law 
provides some evidence that some groups may have concerns 
about the use of their biological materials in research. The 
Havasupai, for example, were willing to have their biological 
materials used for some purposes (i.e., diabetes research), but 
objected to others,236 and thus would likely not agree with 
Wendler’s proposal for a one-time general consent. The 
empirical data provide other support for this view. A 2004 
study among Native Hawaiians found that Native Hawaiians 
were more likely than whites (in a national sample) to want 
researchers to ask their permission to use their biological 
materials in research.237 A 2006 study looking at differences 
between African-American and white cancer patients found no 
differences in reported willingness to donate materials, 
reporting that 95% were willing to do so.238 However, the study 
did find significant differences between the groups on some 
issues. In particular, participants from the hospital with the 
predominantly African-American population were more 
concerned than those from the hospital with a predominantly 
white population that researchers might discover genetic 
                                                          
 235. Id.  
 236. See discussion supra Section II.d. 
 237. Megan Fong et al., Native Hawaiian Preferences for Informed Consent 
and Disclosure of Results from Research Using Stored Biological Specimens, 11 
PAC. HEALTH DIALOG 154, 156 (2004). 
 238. Rebecca D. Pentz et al., Research on Stored Biological Samples: Views 
of African American and White American Cancer Patients, 140 AM. J. MED. 
GENETICS PART A 733, 735 (2006). Contra Donna T. Chen et al., Research with 
Stored Biological Samples: What Do Participants Want?, 165 ARCHIVES 
INTERNAL MED. 652, 654 (2005) (finding a difference between African-
American and non-Hispanic whites’ willingness to donate biological materials, 
75% vs. 88% p=0.002). In the Chen et al. study, only about one-quarter of 
participants were healthy volunteers; the majority were patients or their 
family members. All were participating at research studies through the 
Warren G. Magnuson Biomedical Center, National Institutes of Health. These 
factors may have increased the willingness of people to donate. 
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information about their racial or ethical group (36% vs. 10%, 
p<0.001).239 They also were more likely to express concerns that 
research interests might take precedence over clinical care, 
either by taking more tissue than needed (46% v. 26%, p<0.001) 
or by using tissue in research that was needed for clinical care 
(37% vs. 21%, p=0.0046).240 The researchers found that people 
from the predominantly African-American hospital who 
completed the tissue consent (as part of their surgical 
paperwork) but refused to participate in their study were more 
likely to refuse to donate their biological materials than those 
from the predominantly white hospital.241 Importantly, about 
one-quarter of both groups who were actually offered a chance 
to donate materials for research failed to do so, indicating that 
even when a majority of people are willing to donate materials 
for research, a significant minority will not donate. It is also 
important that participants in that study were all cancer 
patients, who, for a variety of reasons, may be more willing to 
donate their biological materials to research.242 In a 2001 study 
among Jewish Americans, the researchers found that a 
majority of respondents wanted consent as a requirement for 
research use.243 Contrary to the regulatory framework, they felt 
it was more important to obtain consent for materials collected 
in the clinical context that may be used for research rather 
than in research context, presumably because, in the latter 
case, the donor already knows that the materials will be used 
in research.244 Participants also felt that consent was more 
important when research related to genetic traits that may be 
stigmatizing, compared to research on genetic traits that 
caused physical illness or non-stigmatizing genetic traits. 
                                                          
 239. Pentz et al., supra note 238, at 737. 
 240. Id. 
 241. Id. at 739. 
 242. Cancer patients undergoing treatment may be particularly aware of 
and interested in medical research that may improve treatments, may 
appreciate how previous patients’ participation in research may benefit them, 
and may be more likely to agree to participation if their doctors, many of 
whom may also be researchers, ask them to participate. 
 243. Marc D. Schwartz et al., Consent to the Use of Stored DNA for Genetics 
Research: A Survey of Attitudes in the Jewish Population, 98 AM. J. MED. 
GENETICS PART A 336, 338 (2001). 
 244. Id. at 341. It is important to note that this study had a low (20%) 
participation rate and, as a result, a relatively small (273 participants) sample 
size. 
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D.  IMPLICATIONS 
Taken together, the IRB Chair and investigator studies 
suggest a reluctance within the research community to take 
advantage of the portions of the federal regulations governing 
human subjects research and corresponding OHRP guidance 
that permit research with human biological materials without 
consent. Importantly, these practices appear to be more 
responsive to the preferences of those individuals who provide 
their materials for use in research than the approaches 
authorized by the regulations and guidance. The IRB Chair and 
investigator studies also suggest that research using human 
biological materials can be conducted despite the reluctance we 
found to rely on the flexibility in the regulations. This suggests 
that, contrary to the concerns expressed in case law,245 the 
legal framework could be changed to better account for 
participant preferences and IRB Chair and investigator ethical 
intuitions without impeding important research. 
V.  RECOMMENDATIONS FOR CHANGE 
The foregoing analysis demonstrates that current legal 
approaches regarding use of biological materials for research 
are, to some extent, at odds with research practices and 
research participant preferences. The question is whether that 
is a difference that needs to be addressed. It is generally 
understood in the research ethics community that the 
regulations represent a floor; IRBs can and do impose higher 
standards if they think doing so is warranted. For example, an 
IRB may review a research protocol at the full committee level, 
even though it falls within one of the categories of research that 
may be reviewed by the IRB Chair or subcommittee of the IRB 
on an expedited basis.246 In the biological materials research 
context, IRBs are free to require consent for research involving 
stored biological materials when such consent is not required 
by the regulations. Thus, is changing the existing regulatory 
framework necessary to adequately protect biological materials 
donors’ interests? 
There are reasons to believe regulatory changes are 
                                                          
 245. See, e.g., Moore v. Regents of the Univ. of Cal., 793 P.2d 479 (Cal. 
1990); Greenberg v. Miami Children’s Hosp. Research Inst., Inc., 264 F. Supp. 
2d 1064 (S.D. Fla. 2003); Wash. Univ. v. Catalona (Catalona II), 490 F.3d 667 
(8th Cir. 2007). 
 246. For an expedited review, see 45 C.F.R. § 46.110 (2008). 
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warranted to protect the interest of donors in their biological 
materials. First, not all IRBs will review such research at the 
higher level.247 Our IRB Chairs Study provides additional 
support for this concern given that a few Chairs expressed no 
concerns regarding the hypothetical study that would use 
biological materials collected for Alzheimer’s research in 
schizophrenia research. Second, to ignore public preferences 
and interests may undermine trust in research. The current 
regulatory structure is inconsistent with public preferences, 
given that it permits research with biological materials to go 
forward without consent. A widely publicized complaint about 
research use of biological materials could hinder other 
research.248 Finally, as the legal cases demonstrate, courts have 
not recognized donors’ continuing interests in their biological 
materials. The current regulatory framework may contribute to 
this failure. The current regulatory framework generally fails 
to recognize donors’ interests by excluding much research with 
biological materials from its protections.  Regulatory 
recognition of donors’ interests may advance them in two ways: 
by making it less likely that donors’ interests will be 
compromised by researchers in the first place because of 
regulatory protections and by providing a legal foundation for 
building legal claims should materials be used 
inappropriately.249 
                                                          
 247. There is an extensive literature regarding the variability among IRBs 
in terms of their interpretation of the regulations. See, e.g., Rita McWilliams, 
Problematic Variation in Institutional Review of a Multicenter Genetic 
Epidemiology Study, 290 JAMA 360, 36066 (2003); INSTITUTE OF MEDICINE, 
PROTECTING DATA PRIVACY IN HEALTH SERVICES RESEARCH 5256 (2000). 
 248. Negative publicity has been a problem in other areas of research. For 
example, gene transfer research was impacted by the death of Jesse Gelsinger 
in a gene transfer trial at the University of Pennsylvania. See Mark 
Yarborough & Richard R. Sharp, Public Trust and Research a Decade Later: 
What Have We Learned Since Jesse Gelsinger’s Death?, 97 MOLECULAR 
GENETICS & METABOLISM, 4, 45 (2009); Jennifer Couzin & Jocelyn Kaiser, 
Gene Therapy: As Gelsinger Case Ends, Gene Therapy Suffers Another Blow, 
307 SCI., 1028 passim (2005). Similarly, concerns were raised about stem cell 
research following allegations of research misconduct against Woo Suk Hwang 
of South Korea. See David Cyranoski, South Korean Scandal Rocks Stem Cell 
Community, 12 NATURE MED. 4 (2006). 
 249. Plaintiffs have been forced to articulate, for example, property claims 
with respect to their biological materials that have been uniformly 
unsuccessful. Others have commented on the ill fit between the property 
claims and the plaintiffs’ interests. See, e.g., Sonia M. Suter, Disentangling 
Privacy from Property: Toward a Deeper Understanding of Genetic Privacy, 72 
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While there are important reasons for changing the 
regulations to better recognize the continuing interests donors 
may have in their biological materials used for research, there 
are countervailing interests and a balance must be struck. Our 
empirical data regarding current research preferences and 
practices provide some reassurance that requiring more 
oversight of research involving biological materials than 
currently is required under the regulations will not prevent 
such research from going forward. On the other hand, requiring 
consent to each research use or requiring full committee review 
of all such protocols may impose significant burdens with 
respect to review.  This may also add to the cost of research, as 
well as potentially delay it, without significantly increasing 
protections to the donors of the biological materials. Indeed, it 
is important to remember that, although people want to be 
asked whether their biological materials can be used in 
research, most people do not object to most research uses and 
would be satisfied with a one-time, blanket consent to research 
use. Requiring them to consent to each individual research 
protocol, for example, may be unduly burdensome to donors 
and could even create a disincentive to participation. The 
following recommendations seek to recognize the interests and 
concerns some donors may have in the continuing use of their 
biological materials in research, without unduly burdening the 
research or other participants. 
Amend the regulations to bring research involving 
biological materials within the definition of “human subjects 
research” (and thus subject to IRB review). The current 
exceptions to IRB review for much research involving biological 
materials are no longer justified, fail to recognize donors’ 
continuing interest in their biological materials and the ways in 
which they are used, and unnecessarily remove such research 
from the protections afforded by IRB review. As described 
above, the regulatory exceptions for research involving 
biological materials are based on the materials being stripped 
of their identifiers or provided to researchers without 
identifiers and the existence of a strict agreement not to share 
identifying information. However, recent advances in DNA 
technologies suggest that deidentification may not be feasible. 
Only a few SNPs are needed to identify an individual, and 
scientists have demonstrated that it is possible to identify 
                                                          
GEO. WASH. L. REV. 737, 737 (2004). 
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individual DNA even among samples that include DNA from 
multiple sources250 The proliferation of DNA databases 
increases the risk to potential donors whose materials are used 
in a deidentified manner. For example, the U.S. military 
currently collects DNA from all personnel. The primary 
purpose of these samples is to enable identification of remains, 
but it is possible that at least some data may become available 
for research purposes. Similarly, federal and state governments 
have been collecting DNA samples from persons convicted of 
crimes for law enforcement purposes for years. They are now 
expanding those collections to those who are arrested – a 
substantial expansion.251 Given these changing circumstances, 
it is difficult to justify the regulatory exceptions for research 
with biological materials and deprive those donating materials 
from the protections offered by IRB review. 
Moreover, excluding much research involving biological 
materials from human subjects research, the current regulatory 
treatment disregards donors’ continuing interests in their 
biological materials. Contrary to the assumptions underlying 
the regulatory treatment, donors do care about how their 
biological materials are used. They want to know whether the 
materials are going to be used in research in the first place.A 
significant minority also objects to some research uses. 
Bringing this research more fully within the human subjects 
research framework would recognize the donors’ continuing 
interests and provide the structure to protect those interests 
(e.g., IRB review). 
There are several steps needed to achieve this goal. The 
first step is to revoke the OHRP guidance that specifies that 
genetic research involving stored biological materials is not 
“human subjects” research when samples or data are 
deidentified or coded, but identifiers are not shared.252 The 
second step is to amend 45 C.F.R. § 46.101(b)(4) of the federal 
                                                          
 250. See discussion supra Section III.b. 
 251. Moore, supra note 199, at A1. Although they may be collected for one 
purpose, there is little reason to believe that such materials will be used in 
such a limited fashion. See D.H. Kaye, Behavioral Genetics Research and 
Criminal DNA Databases, 69 LAW & CONTEMP. PROBS. 259, 25960 (2006) 
(suggesting that DNA records in law-enforcement databases originally 
obtained for identification purposes might one day be used in behavioral 
genetics research). 
 252. Guidance, supra note 174. 
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regulations to eliminate the exemption for use of pathological 
specimens or diagnostic specimens. It will require some effort 
to amend the regulations; the process requires public notice 
and comment periods. These considerable efforts may explain 
the limited amendments that have been made over the years 
that the regulations have been in effect. Given these 
challenges, it may be possible that OHRP could issue guidance 
that makes clear that biological materials containing DNA 
cannot be rendered unidentifiable (thus, rendering this 
exemption inapplicable), at least as a temporary measure. 
That such research should be subject to IRB review does 
not mean that all research must undergo full committee 
review.253 While I am arguing that research involving stored 
biological materials should always be considered human 
subjects research within the meaning of the federal regulations 
and should not be exempt from review, there are many 
circumstances in which the risks presented by such research 
will be quite limited. Specifically, when biomaterials are stored 
in a central repository, under an IRB-approved protocol, we can 
have some confidence that the interests of the donors of human 
biological materials will be protected. This is because the IRB 
has already reviewed and approved the processes for collecting 
the materials with donors’ consent and for distributing 
materials for research use. IRB review of secondary research 
uses of the material can be limited, using expedited review. 
Such review should focus on evaluating whether the proposed 
                                                          
 253. There are three potential levels of review under the federal 
regulations. Although not required under the regulations, federal guidance 
indicates that research that is eligible for exemption should be reviewed by an 
IRB to confirm the eligibility. Such review may be conducted by a 
knowledgeable individual. United States Dept. of Health & Human Services, 
http://www.hhs.gov/ohrp/policy/exempt_res_det.html (last visited Feb. 15, 
2010). The regulations permit research that presents no more than minimal 
risk and falls within specified categories to be reviewed under expedited 
review procedures. See, 45 C.F.R. § 46.110 (2008). For a detailed list of 
categories of research eligible for expedited review, see Protection of Human 
Subjects: Categories of Research that May Be Reviewed by the Institutional 
Review Board (IRB) Through an Expedited Review Procedure, 63 Fed. Reg. 
60364, 6036466 (Nov. 9, 1998). Such review may be completed by a 
subcommittee of the IRB and may be reviewed outside a plenary meeting. 
Finally, all other research must be reviewed by a quorum of the full IRB 
committee at a plenary meeting. Institutions have been criticized for failing to 
review research protocols as required under the regulations. See, e.g., Nancy 
Kass et al., Controversy and Quality Improvement: Lingering Questions About 
Ethics, Oversight, and Patient Safety Research, 34 JOINT COMM’N J. ON 
QUALITY & PATIENT SAFETY 349, 35052 (2008). 
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use is consistent with the uses agreed to in the consent and 
whether the project poses any new or unique risks that might 
not have been contemplated when the materials were donated. 
Requiring this limited level of IRB review, beyond that which 
the biorepository must conduct as part of its operations 
provides a check on the biorepository processes, as well as 
providing an opportunity to identify new or changing risks that 
may require attention at the individual protocol or at the 
biorepository level. Should changes be necessary, the IRB 
would be in a position to identify them and request them of 
either the specific research protocol or the overarching 
biorepository protocol. 
Requiring consent to research use. A corollary to the first 
recommendation for treating research involving biological 
materials as human subjects research is that no biological 
materials should be used in genetic research without consent 
from the donor of the materials. This recommendation 
represents a significant change from the existing regulatory 
framework, which allows biological materials collected for other 
purposes (e.g., blood drawn for clinical purposes) to be used in 
research. However, the lessons from the legal cases and 
empirical research on public preferences are that people want a 
say in whether their biological materials are used in research, 
especially when those materials were initially collected for 
other purposes. Moreover, some people find some research uses 
highly objectionable, even when the samples are not directly 
identifiable. The anecdotal evidence from the legal cases and 
the data from the empirical research on public preference 
undermine the assumption supporting the regulatory 
exceptions.254 
Nevertheless, requiring consent does not necessarily mean 
that donors of biological materials need to consent to each and 
every research use. Indeed, the majority of people do not want 
such a role and, to large extent, it seems unlikely that doing so 
                                                          
 254. Other commentators have suggested that tissue collection is not 
research and that other rules are needed. Leonard Glantz et al., Rules for 
Donations to Tissue BanksWhat Next?, 358 NEW ENG. J. MED. 298, 30203 
(2008). It is true that some tissue collection is not research. For example, 
biological materials often are obtained for clinical purposes from biopsies or 
blood draws. If they are used solely for clinical purposes, their use is non-
controversial. The problems that have arisen, including the cases of Moore, 
Greenberg, and Catalona have arisen in connection with research uses. 
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will provide additional protections to individuals, though it will 
certainly add substantially to the burden on research.255 On the 
other hand, a one-time general consent, proposed by Wendler 
and others, may not provide adequate protection to donors. 256  
For example, a general consent would have authorized the 
uses, such as the migration studies, to which the Havasupai 
had the strongest objections. Even those research participants 
who generally support research and were willing to give 
general consent might have second thoughts based on scientific 
developments. For example, some may be concerned about the 
increasing identifiability of their samples. Others may be more 
concerned about potential use of their materials in new types of 
research, such as stem cell research, that was not possible 
when they gave their consent.257 
There are some approaches discussed in the literature that 
address these competing concerns of donor protection and 
facilitating scientific research.258 The first is to have a robust 
consent process that gives individuals a good sense of the types 
of research that their materials may be used for, as well as 
where the uncertainties lie. Giving donors an opportunity to 
express their preferences about future research, as 
recommended in the literature and embraced in practice,259 is a 
way to respect individuals’ interests while facilitating research. 
Soliciting these preferences provides some basis on which the 
biorepositories that house these materials and the IRBs that 
oversee them can make choices about what uses are 
appropriate and consistent with the donors’ consent. The 
challenge will be defining categories of research sufficiently so 
that donors of materials and IRBs can determine what uses are 
                                                          
 255. Timothy Caulfield et al., Research Ethics Recommendations for Whole-
Genome Research: Consensus Statement, 6 PLOS BIOLOGY 430, 43132 (2008). 
 256. E.g., Wendler, supra note 234, at 54647; Mats G. Hansson et al., 
Should Donors Be Allowed to Give Broad Consent to Future Biobank 
Research?, 7 LANCET ONCOLOGY 266, 26869 (2006). Contra Timothy 
Caulfield, Biobanks and Blanket Consent: The Proper Place of the Public Good 
and Public Perception Rationales, 18 KING’S L. J. 209, 21524 (2007) (laying 
out an excellent critique of the blanket consent position). 
 257. See, e.g., Bernard Lo et al., Informed Consent in Human Oocyte, 
Embryo, and Embryonic Stem Cell Research, 82 FERTILITY & STERILITY 559, 
56062 (2004). For example, British researchers recently announced that they 
had developed sperm from human embryonic stems cells. Cell Medicine, supra 
note 1. 
 258. See sources cited supra note 253. 
 259. See NBAC, supra note 2; Wolf et al., supra note 221. 
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permitted.260 At the edges, IRBs need to act in favor of 
protection, as the data from our IRB Chair Study suggest that 
they do. 
The second approach is to have a mechanism for 
accounting for changing circumstances. New types of research 
may be developed, such as stem cell research and some 
behavioral genetic research, that were not anticipated and are 
controversial.261 Scientific developments may alter our 
understanding; for example, recent developments suggest that 
we may not be able to conduct research with “deidentified” 
samples. These changes may require that we re-contact those 
who have provided materials, inform them of the change 
circumstances, and readdress their preferences and willingness 
to have their materials used.262 Adopting this approach 
requires that we ask donors for permission to re-contact them 
and ask for their contact information. Some participants may 
object to recontact and, thus, use of their materials may be 
limited in the future. However, technology makes re-contact 
more feasiblecheaper and easier than before. Indeed, there 
may be scientific benefits to maintaining contact with donors of 
biological materials, and not just when there are developments 
that might change people’s willingness to allow their materials 
to be used in research. Some commentators have been arguing 
for on-going contact.263 Such contact need not be individual; for 
example, biobanks may provide aggregate information about 
research projects for which materials have been used. A 
significant development that might justify revisiting consent 
might appropriately be conducted on an opt-out basis; that is, 
providing relevant information and requesting anyone who 
objects to continued use to contact the biobank. 
Changing the consent processes for research use of 
biological materials only works for some 
                                                          
 260. E.g., Caulfield et al., supra note 265, at 43133; Darren Shickle, The 
Consent Problem Within DNA Biobanks, 37 STUD. HIST. & PHIL. BIOLOGICAL 
& BIOMED. SCI. 503, 505–07 (2006) . 
 261. See Amy L. McGuire et al., Research Ethics and the Challenge of 
Whole-Genome Sequencing, 9 NATURE REVS. GENETICS 152, 155 (2008)  
(describing implication of whole genome sequencing for research ethics, 
particularly the consent issue). 
 262. Shickle, supra note 260, at 507. 
 263. E.g., Timothy Caulfield et al., DNA Databanks and Consent: A 
Suggested Policy Option Involving an Authorization Model, 4 BMC MED. 
ETHICS 1, 23 (2003); Shickle, supra note 260, at 507. 
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circumstancesprospective collections or existing collections 
for which there is contact information, such that re-contact is 
feasible. That may eliminate many biological materials from 
future use, especially older materials, which may be a profound 
scientific loss.264 Accordingly, we may need to consider other 
means of taking into account donor interests. Some have 
suggested community consultation as a way of doing so.265 For 
example, some Chairs in our study suggested that remaining 
members of the sample or representatives of the Alzheimer’s 
community could be consulted about the proposed use of the 
materials for schizophrenia research. The challenge, of course, 
is in identifying the relevant community and appropriate 
representatives.266 For example, it should be obvious that 
community consultation on the use of Havasupai samples 
would not be valid if it did not contain any Native Americans. 
However, it may be less clear how closely related the 
representative must be to the donor group. For example, would 
it be acceptable to have a consultation that included no 
Havasupai, but includes other Native American nations? Could 
a member of a different (perhaps larger) tribe adequately 
represent the Havasupai’s interests? What if there were only 
one Havasupai (or other Native American) in the group? In the 
hypothetical in our IRB study, would family members of 
                                                          
 264. On the other hand, older materials may be more available for research 
if the donors are dead; the federal regulations on human subjects research 
apply only to living individuals. 45 C.F.R. § 46.102(f) (2008). Nevertheless, 
even those donors may have continuing interests that ought to be considered 
through the alternative means discussed in this paragraph. Meslin & Quaid, 
supra note 2, at 230. 
 265. E.g., NBAC, supra note 2, at 78.   
 266. This is not a new issue. IRBs are required to have a non-affiliated 
member, a requirement that is typically interpreted as that for a “community” 
member who can represent the interests of potential research participants. See 
Sohini Sengupta & Bernard Lo, The Roles and Experiences of Nonaffiliated 
and Non-Scientist Members of Institutional Review Boards, 78 ACAD. MED. 
212, 21316 (2003).  HIV and international researchers, among others, have 
relied on community advisory boards for feedback on community mores, 
preferences, and priorities. Stephen F. Morin et al., Community Consultation 
in HIV Prevention Research: A Study of Community Advisory Boards at 6 
Research Sites, 33 J. ACQUIRED IMMUNE DEFICIENCY SYNDROME 513, 51415 
(2003). Community-based participatory research engages the community to set 
research agendas, design community-appropriate research protocols, and 
return research results to the community. In each of these settings, there have 
been questions raised about what are the relevant communities and who 
represents them. See, e.g., Caitlin Kennedy et al., Faculty Perspectives on 
Community-Based Research: “I See This Still as a Journey”, 4 J. EMPIRICAL 
RES. ON HUM. RES. ETHICS 3, 6 (2009). 
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Alzheimer’s patients be adequate representatives of the donors’ 
interests or do donors need to be represented more directly 
(e.g., early Alzheimer’s patients who were not part of the 
original sample)? Despite these challenges, we need to identify 
alternative methods for identifying and protecting donors’ 
interests in existing collections. More research may be needed, 
but the potential scientific benefits require it. 
Robust right to withdraw biological materials. Requiring 
ongoing communication with donors of biological materials and 
revisiting consent in some circumstances only makes sense if 
there is a robust right to withdraw biological materials. The 
federal regulations governing human subjects research should 
be understood to include such a right. They explicitly require 
that participants be told that they “may discontinue 
participation at any time without penalty or loss of benefits to 
which the subject is otherwise entitled.”267 In the case of 
biobanking, when the subjects’ only participation is 
contribution of their biological materials, this requirement only 
makes sense if it means that they can ask that their materials 
be withdrawn from further research use. 
As described above, however, the Catalona opinions call 
into question this right. Indeed, the district court concluded 
that 
[T]he right to discontinue participation in a research project means 
nothing more that the [research participant] has chosen not to provide 
any more biological materials pursuant to one or more research 
protocols . . . . Nothing more can or should be read into this right 
possessed by the [research participant] at all times.268 
The court of appeals focused on whether the participants 
had a right to physical return of their biological materials and 
concluded, for a host of good reasons,  that they did not.269 
Thus, it never turned its attention to what the right to 
withdraw means when biological materials have been donated. 
The Havasupai case illustrates the importance of having a 
robust ability to withdraw.  In the on-going communication, the 
researchers should have notified the Havasupai that the 
materials were going to be used in new projects on 
                                                          
 267. 45 C.F.R. § 46.116(a)(8) (2008). 
 268. Wash. Univ. v. Catalona (Catalona I), 437 F. Supp. 2d 985, 1000 (E.D. 
Mo. 2006). 
 269. Wash. Univ. v. Catalona (Catalona II), 490 F.3d 667, 675–77 (8th Cir. 
2007), cert. denied, 128 S.Ct. 1122 (2008). 
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schizophrenia and migration. Having learned that their 
materials might be used in ways they found objectionable, the 
Havasupai would have the opportunity to withdraw their 
materials. If the researchers could simply remove identifiers 
and continue with the research, the Havasupai would still be 
harmed. Confidentiality was not their sole concern. Only by 
being able to remove the materials entirely can they protect 
their interests and avoid harm. That is not to say that 
removing identifiers and continuing to use biological materials 
in research is always wrong. Some donors may be concerned 
only with confidentiality and may feel that removing identifiers 
(and strong agreements not to try to re-identify materials) is 
sufficient to address their concerns. However, the default 
response when someone makes the effort to withdraw their 
biological materials cannot be to remove identifiers and 
continue to use them. Rather, donors should be specifically 
asked whether they want their materials withdrawn entirely 
from research or whether they would agree to their continued 
use if their identifiers were removed. Of course, they should 
also be informed of the limitations of deidentification. 
In light of the ambiguity created by the Catalona cases, the 
right to withdraw biological materials needs to be clarified. 
OHRP should issue guidance that makes clear that people who 
donate their materials have a right to withdraw them and that, 
when such requests are made, it is impermissible to continue to 
use them in de-identified fashion without the donors’ explicit 
permission. Some qualifications are necessary. Biological 
materials may be finite; if the materials are used up before the 
request to withdraw is made, withdrawal may not be not 
feasible. In other instances, identifiers may have been removed 
from biological materials in such a way that reidentification is 
not reasonably feasible,  although given scientific and 
technological advances, this limitation may not amount to 
much in the future. While OHRP guidance is an appropriate 
first step to help prevent the Catalona misinterpretation of the 
regulations from continuing, ultimately it would be preferable 
to amend the regulations to specify that the right to 
withdrawbiological materials that are collected and stored 
pursuant to a research protocol means that those materials can 
no longer be used in research. 
Despite court opinions to the contrary, changing the 
regulatory framework concerning use of biological materials in 
research to better respect individuals’ preferences and interests 
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in the biological materials is unlikely to stifle important 
research. Indeed, such research depends on the willingness of 
the public to trust researchers with their materials. The 
evidence suggests that the public trust requires the recognition 
that research on stored samples is human subjects research 
and should be afforded all concomitant protection, including the 
right to withdraw samples for research use. 
